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CHAPTER 1:  Introduction 
 
Research problem 
It is our goal to further the understanding of methyl group and homocysteine metabolism 
as it relates to health and disease.  This necessitates investigation into the factors that alter 
methyl group metabolism and identification of potential adverse effects of these metabolic 
aberrations.  Previous research within our lab group and by others has demonstrated that 
both administration of retinoids or a diabetic condition acutely perturbs hepatic methyl group 
and homocysteine metabolism.  Specifically, both conditions upregulate glycine N-
methyltransferase (GNMT), an enzyme proposed to be a key regulator of methyl group 
supply and utilization.  It was our hypothesis that sustained induction of GNMT, by 
either retinoids or a diabetic condition, would lead to a functional methyl deficiency, 
whereby methyl groups would be unavailable for other methyltransferase reactions, 
such as DNA methylation.  The methylation of DNA is an important component of 
epigenetic regulation of the genome.  Epigenetic events, such as altered DNA methylation 
status, cause heritable changes in gene expression without changing the DNA sequence.  
Epigenetic marks are also associated with the maintenance of genome stability.  We 
expected that changes in epigenetic regulation, i.e. DNA methylation would be associated 
with adverse effects, such as hepatotoxicity.  Aberrant epigenetic regulation also represents 
a possible mechanistic link to the development of the secondary complications of diabetes, 
which will be addressed in future studies.  The aim of the studies presented here was to 
characterize methyl group and homocysteine metabolism by assessing key regulatory 
enzymes and metabolites, as well as epigenetic regulation by DNA methylation, in rats 
treated with all-trans-retinoic acid (RA) for up to six months, as well as in the streptozotocin 
(STZ)-induced (type 1) diabetic and Zucker (type 2) diabetic fatty (ZDF) rats.   
 
Significance 
 The results of these studies offer insight into the safety of RA treatments and the 
pathogenesis of type 1 and type 2 diabetes.  This knowledge could impact the course of 
treatment for many patients.  Retinoids are widely used for treatment of dermatological 
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conditions and in cancer chemotherapy, but these treatments have many side effects and 
safety of the retinoid compounds is still a matter of debate.  Diabetes has been established 
as a serious public health concern with estimates that 12% of the U.S. population has the 
disease and the prevalence of diabetes is rising, both in the U.S. and worldwide.  Diabetes 
is associated with increased morbidity and mortality due to metabolic perturbations of the 
disease and the development of secondary complications including cardiovascular disease, 
nephropathy, neuropathy, and retinopathy.  By furthering the understanding of methyl group 
and homocysteine metabolism in these conditions, it is our hope that this information might 
be used for the formulation of appropriate dietary therapies to minimize adverse effects and 
development of secondary complications. 
 
Dissertation organization 
 Following a review of the literature, this dissertation will include three chapters 
consisting of manuscripts that have been prepared for publication in peer-reviewed journals.  
The first article will be submitted to Hepatology and presents an investigation of the effects 
of chronic retinoid treatment on hepatic methyl group metabolism, DNA methylation status, 
and general markers of toxicity in rats.  The second manuscript details a time course study 
of aberrant methyl group metabolism and DNA methylation in the STZ-induced rat model of 
type 1 diabetes.  This article was published in the Journal of Nutrition in November 2008.  
The third, and final, paper describes the characterization of methyl group and homocysteine 
metabolism, as well as epigenetic regulation in the liver, kidney, and heart of the ZDF rat 
during early and advanced diabetic conditions.  This article has been prepared for 
publication in the American Journal of Physiology – Endocrinology and Metabolism.  
Following this third manuscript will be an overall summary and conclusions statement which 
presents a thorough discussion of the results, proposes potential regulatory factors, and 
suggests potential future research directions. 
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CHAPTER 2:  Literature review 
 
Methyl group and homocysteine metabolism 
 The metabolism of homocysteine and regulation of methyl balance are fundamental 
processes in the maintenance of health.  Dietary methyl donors include methionine, folate, 
betaine, and choline.  Utilization of methyl groups from these sources and the metabolism of 
homocysteine rely on transmethylation, remethylation, and transsulfuration pathways 
(Figure 1).  Transmethylation begins with the activation of methionine to S-
adenosylmethionine (SAM) via addition of an adenosyl group by methionine 
adenosyltransferase (MAT).   SAM can then donate a methyl group to a variety of methyl 
acceptor molecules, resulting in a methylated product and S-adenosylhomocysteine (SAH).  
Homocysteine is produced by the hydrolysis of SAH by S-adenosylhomocysteine hydrolase 
(SAHH).  Homocysteine can be recycled to methionine by folate/B12-dependent or –
independent pathways.  The folate/B12-dependent pathway utilizes a methyl group provided 
by 5-methyltetrahydrofolate (5-CH3-THF) via the methylcobalamin cofactor of methionine 
synthase (MS).  Methylenetetrahydrofolate reductase (MTHFR) synthesizes the 5-CH3-THF 
substrate from 5,10-methylenetetrahydrofolate (5,10-CH2-THF), which is a branch point in 
folate metabolism and is also used for thymidylate synthesis. Remethylation by folate/B12-
independent means is catalyzed by betaine-homocysteine S-methyltransferase (BHMT) and 
utilizes betaine as a methyl donor.  In addition to dietary sources, betaine can be derived 
from choline by the action of choline oxidase; thereby choline is also indirectly a methyl 
donor for the BHMT reaction.  As an alternative to remethylation, homocysteine may also be 
catabolized to cysteine by the transsulfuration pathway enzymes cystathionine β-synthase 
(CBS) and cystathionine γ-lyase (CGL), both of which are B6-dependent enzymes.  
Understanding the regulation and physiological significance of each pathway, as well as the 
interrelationships between pathways, is an important and active area of research. 
 
  
Transmethylation  
The condensation of methionine with adenosine is catalyzed by any of the three 
isoforms of MAT.  The isoforms of MAT are functionally different based on their kinetic 
properties and tissue-specificity (1
(Km), whereas MAT III has a high K
under normal intracellular methionine concentrations.  
MAT III isoform is not subject to product inhibition by SAM
-3).  MAT I and MAT II have a low Michaelis constant 
m.  MAT I and MAT II function at near maximal capacity 
In addition, unlike MAT I and II, the 
 and thus, is uniquely able to 
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continue to use more substrate as methionine load increases.  MAT II is specific to 
extrahepatic tissues, whereas MAT I and III are expressed in the liver.  The presence of 
MAT III in the liver is just one of many pieces of evidence that suggests a key role for the 
liver in regulating methyl supply and utilization. 
 Following the activation of methionine to SAM by MAT, SAM can be used in a variety 
of transmethylation reactions.  There are purported to be >100 SAM-dependent 
methyltransferases, over 30 of which have been characterized (4).  Transmethylation 
reactions take place in all cells and involve the transfer of a methyl group from SAM to a 
methyl acceptor, resulting in the generation of the methylated product and SAH.  Methyl 
acceptors include lipids, proteins, nucleic acids, and other small molecules.  Lipids produced 
by transmethylation reactions include phosphatidylcholine, which is a vital component of 
membranes, bile acids, and lipoproteins, and involved in cell signaling (5).  Methylated 
proteins include cellular receptors, histones, and transcription factors (6).  SAM-dependent 
transmethylation reactions are also responsible for the methylation of non-coding and 
coding RNAs, as well as the establishment and maintenance of DNA methylation patterns 
(7,8).  Other small molecules that are methylated include the neurotransmitters of the 
serotonin and catecholamine pathways (9) and ubiquinone in the mitochondria (10).  This 
list highlights just a few of the biologically important molecules derived from or modified by 
SAM-dependent transmethylation reactions. 
In addition to these varied methylated products, all transmethylation reactions 
produce SAH.  This product can be hydrolyzed to homocysteine and adenosine by SAHH.  
This reaction is bidirectional and favors the formation of SAH, but proceed towards 
homocysteine with the removal of the products (11).  Elevated levels of both SAH and 
homocysteine have been associated with the development of disease, including 
neurological disorders, vascular diseases, and renal dysfunction (12-16).  Therefore, 
regulation of the production of these metabolites is critical.   
There are three methyltransferases that have been proposed to be major 
contributors to the regulation of methyl group and homocysteine metabolism: 
guanidinoacetate methyltransferase (GAMT), phosphatidylethanolamine N-
methyltransferase (PEMT), and glycine N-methyltransferase (GNMT).  It has long been 
known that GAMT and PEMT catalyze the most quantitatively significant SAM-dependent 
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transmethylation reactions under normal physiological conditions (17).  GAMT facilitates the 
transfer of one methyl group from SAM to guanidinoacetate to form creatine, a ready source 
of energy for cells.  Traditionally, GAMT was thought to be the largest single consumer of 
methyl groups from SAM (17), but Stead et al. (18) have recently summarized evidence 
which suggests that PEMT may be a larger consumer of methyl groups and more important 
contributor to elevations of homocysteine than GAMT.  In addition to methodological 
questions regarding earlier studies, it is noted that creatine can also be supplied in the diet.  
Their study of creatine supplementation in rats demonstrated decreased guanidinoacetate 
synthesis, a 90% decrease in GAMT activity, and 25% decrease in plasma homocysteine 
levels (19).  Subsequent studies in rats have also shown decreases in plasma homocysteine 
(20; Nonnecke & Schalinske, unpublished observations). However, studies in humans have 
provided conflicting results.  Unexpectedly, two recent studies have shown creatine 
supplementation to be associated with increases in plasma homocysteine levels in two very 
different subject populations: healthy young men (21) and patients with coronary artery 
disease (22).  Of the remainder of human studies of creatine supplementation, one found a 
small, but significant decrease in plasma homocysteine (23), whereas others found no effect 
(24) or were inconclusive due to confounding factors such as renal disease and use of 
dietary supplements (25). 
The reaction catalyzed by PEMT – the other proposed regulator of homocysteine 
levels -  consists of the sequential addition of three methyl groups to 
phosphatidylethanolamine (PE), thereby consuming three molecules of SAM and generating 
three molecules of SAH, as well as the product phosphatidylcholine (PC).  Under normal 
physiological conditions, PEMT is estimated to generate one-third of PC produced and the 
remainder is produced via the CDP-choline pathway (26).  Cytidylyltransferase-α (CTα) and 
PEMT knockout models have been used to determine the physiological significance of 
altered PEMT activity (27-30).  The rate-limiting step of the CDP-choline pathway of PC 
synthesis is catalyzed by CTα.  Therefore, knocking out CTα would be expected to increase 
PEMT activity for adequate PC synthesis.  Accordingly, in CTα-deficient mice, PEMT activity 
increased 100% and methylation of PE, as measured using radiolabeled methionine, also 
increased 100% (27).  Furthermore, plasma homocysteine levels were elevated 20-40% in 
CTα-deficient mice compared to controls, despite compensatory increases in BHMT activity.  
Likewise, transfection of PEMT into rat hepatoma cells resulted in ~1.5-fold increase in 
homocysteine secretion (28).  Conversely, primary hepatocytes from PEMT -/- mice secreted  
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~50% less homocysteine than cells from wild-type mice and plasma homocysteine levels 
were ~50% lower in both male and female mice deficient in PEMT.  Deficiency of PEMT also 
decreased hepatic levels of choline, choline-containing phospholipids, triglycerides, and 
lipoproteins, as well as altered lipoprotein production and metabolism (29,30).   
Whereas GAMT and PEMT have been most closely linked to homocysteine levels, 
GNMT is a proposed regulator of methyl group supply and utilization (31).  GNMT is 
expressed in kidney, pancreas, and small intestine and is highly abundant in the liver, 
comprising up 1-3% of total hepatic protein (32).  The GNMT tetramer catalyzes the addition 
of a methyl group to glycine, thereby forming sarcosine.  Sarcosine has no clear 
physiological function and can be metabolized by sarcosine dehydrogenase, making it an 
ideal product for disposal of excess methyl groups.  GNMT is also notable in that it is not 
subject to feedback inhibition by SAH unlike most, if not all, other known SAM-dependent 
methyltransferases (31).  Based on these characteristics, accumulating evidence from 
GNMT knockout models, and a unique regulatory relationship with folate metabolism, GNMT 
is proposed to be a primary regulator of the SAM:SAH ratio which governs transmethylation 
potential.   
Two GNMT knockout mouse models have recently been developed, and although 
there is some debate regarding completeness of the knockout and differences in the course 
of pathogenesis in the two models (33), animals from both models exhibit dramatic 
increases in the SAM:SAH ratio and development of hepatocellular carcinoma (HCC; 34-
37).  The Wagner group produced the first published report of a GNMT knockout mouse 
which was characterized by elevated hepatic methionine and SAM concentrations 
concurrent with decreased SAH concentrations, resulting in a 100-fold increase in the 
hepatic SAM:SAH ratio (34).  In the GNMT knockout model developed by Chen’s group, the 
SAM:SAH ratio was elevated 42- and 82-fold in male and female GNMT -/- mice, respectively 
(35).  There was no elevation of the SAM:SAH ratio in heterozygotes in either model, 
despite a 50% reduction in GNMT activity in heterozygotes as reported by Luka et al (34).  
The development of HCC in GNMT knockout mice is postulated to be due to dysregulation 
of DNMTs, DNA and histone methylation, as well as perturbation of canonical signaling 
pathways involved in carcinogenesis including the Wnt, JAK/STAT, and MAPK pathways 
(36,37).  Human HCC and prostate cancer have also been characterized by downregulation 
or lack of GNMT (38-40). 
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Upregulation of GNMT has been postulated to be protective against toxins and 
carcinogenesis.  In addition to its regulatory role in methyl group metabolism, GNMT is also 
a purported 4S polycyclic hydrocarbon-binding protein (41).  Benzo[α]pyrene and aflatoxin 
or their metabolites are aryl hydrocarbons and causal agents of HCC.  Upregulation of 
GNMT in transfected cell lines or a transgenic mouse model decreased toxin-associated 
DNA adduct formation and reduced cytotoxicity or prevented the development of HCC 
(42,43).  In response to the toxins, GNMT was translocated to the nucleus and molecular 
modeling suggested interactions at the SAM-binding site of the dimeric form of GNMT.  
Earlier reports have also shown translocation of GNMT to the nucleus and measured 
significant GNMT activity in nucleic extracts (32), though the role of GNMT in the nucleus 
remains somewhat ambiguous.   
Whereas GAMT does not appear to catalyze the rate-liming reaction of creatine 
synthesis and is proposed to respond largely to guanidinoacetate concentrations (44,45), 
PEMT and GNMT are subject to regulation by a wide variety of hormonal factors.  
Expression and/or activity of PEMT and GNMT are gender-specific or responsive to sex 
hormones (46,47).  GNMT and PEMT are induced by a diabetic condition or treatment with 
glucocorticoids (32,48-52), whereas insulin treatment attenuates this effect (48,50).  As 
another potential function for GNMT, this diabetes-induced upregulation has been proposed 
as a mechanism for the generation of pyruvate from methionine for gluconeogenesis, 
especially as GNMT expression is limited to gluconeogenic tissues (32). However, 
upregulation of GNMT is not specific to a diabetic state.  GNMT activity and expression are 
also altered by growth hormone: activity and mRNA abundance are increased in the Ames 
dwarf mouse which lacks growth hormone, prolactin, and thyroid-stimulating hormone; this 
increase was attenuated by treatment with growth hormone (53,54).  Likewise, 
triiodothyronine normalized elevations in GNMT activity by retinoids, although GNMT 
abundance was unaffected, suggesting posttranslational regulation; neither hypo- nor 
hyperthyroidism had an independent effect on GNMT activity or protein abundance (55). 
There is also a unique regulatory relationship between GNMT and folate metabolism.  
GNMT can be bound by 5-CH3-THF, which inhibits GNMT activity (56), specifically by 
inhibition of phosphorylation which enhances GNMT activity (57).  However, with GNMT 
activity decreased, this would be expected to increase intracellular SAM levels and MTHFR 
is allosterically inhibited by SAM (58).  When methyl group supply is high, SAM levels are 
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elevated and MTHFR is inhibited, thereby decreasing the available methyl groups incoming 
via folate/B12-dependent remethylation.  Furthermore, GNMT activity is freed from inhibition 
by 5-CH3-THF, resulting in lowering of SAM levels and restoration of the SAM:SAH ratio.  
When methyl group supply is low, SAM levels are decreased, relieving the inhibition of 
MTHFR and increasing 5-CH3-THF concentrations, which inhibits GNMT activity and 
provides more substrate for remethylation via MS, thereby increasing the methyl pool.  This 
reciprocal regulation of GNMT and MTHFR is thought to play a key role in transmethylation 
potential homeostasis.   
 
Remethylation 
 Homocysteine can be remethylated by folate/B12-dependent or –independent 
pathways.   In addition to the remethylation of homocysteine to methionine, folate 
metabolism is also involved in the transfer of one-carbon units for the synthesis of purines 
and thymidylate (59).  The C2 and C8 carbons of purines are donated from the formyl group 
of 10-formyltetrahydrofolate in reactions catalyzed by 5-amino-4-imidazole carboxamide 
transformylase and glycinamide ribotide transformylase, respectively.  For thymidylate 
synthesis, formaldehyde is transferred from 5,10-CH2-THF to deoxyuridylate by thymidylate 
synthetase.  Alternatively, MTHFR converts 5,10-CH2-THF to 5-CH3-THF, which is the 
methyl donor for the remethylation of homocysteine to methionine by the folate/B12-
dependent pathway.  The folate/B12-dependent pathway of remethylation appears to be 
active in all tissues and is essential for survival (60,61).  In the attempt at developing a MS 
knockout in two strains of mice, Swanson et al. (61) reported that MS activity was decreased 
40% in heterozygotes relative to controls, but there were minimal effects on plasma 
methionine or homocysteine levels.  There were no viable homozygotes, with loss of the 
embryo occurring shortly after implantation.  It is likely that the failure to survive was due, at 
least in part, to the effects of the “methyl trap” hypothesis, in which folate accumulates as 5-
CH3-THF due to the irreversibility of the MTHFR reaction and lack of other 5-CH3-THF-
metabolizing enzymes and thus, is unavailable for the other critical reactions requiring folate 
coenzymes (59).  This “methyl trapping” phenomenon was first proposed after aberrations of 
folate metabolism were noted in patients and rats lacking adequate vitamin B12, an essential 
cofactor for MS activity.  Unlike the MS knockout model, both hetero- and homozygous 
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MTHFR knockout mice were viable and exhibited elevated plasma homocysteine levels and 
decreased SAM:SAH ratios in liver, brain, ovaries, and testes (62).  The phenotypic effects 
were significantly greater in MTHFR-/- mice, which were developmentally delayed and had 
neural and vascular abnormalities in addition to the 10-fold increase in plasma 
homocysteine.  Taking into consideration the effects on metabolites observed in the MS and 
MTHFR knockout models and the unique relationship between the MTHFR and GNMT, it 
appears that MTHFR has a more significant regulatory role than MS. 
Homocysteine may also be remethylated to homocysteine by the action of BHMT in 
the folate/B12-independent remethylation pathway.  Choline can be converted to betaine by 
choline oxidase and betaine aldehyde dehydrogenase in the mitochondria. Thereby, both 
dietary choline and betaine may serve as methyl donors for this reaction.  BHMT is 
suggested to contribute significantly to the regulation of homocysteine levels.  BHMT is 
primarily a liver-specific enzyme, but can also be found in the kidney in primates and pigs, 
with small amounts expressed in the rat kidney (61).  Although there are no genetic 
knockout models for BHMT, S-(δ-carboxybutyl)-DL-homocysteine is a potent inhibitor of 
BHMT activity and has been used experimentally to determine the effect of BHMT on 
homocysteine levels (64).  A single injection of S-(δ-carboxybutyl)-DL-homocysteine (1 mg) 
in mice was sufficient to decrease BHMT activity 90% and increase homocysteine levels by 
greater than 100% for 1-8 hrs.  There was no effect on MS and CBS activities, suggesting 
that changes in homocysteine could be attributed specifically to the decrease in BHMT 
activity. 
MS and BHMT are regulated by many of the same factors that influence the SAM-
dependent methyltransferases.   The effects of a diabetic condition on MS, MTHFR, and 
BHMT are varied and will be discussed in depth in subsequent sections.  In the growth 
hormone-deficient Ames dwarf mouse, the mRNA expression of BHMT was upregulated, 
whereas MS expression was suppressed (54).  MTHFR activity in the liver and/or kidney is 
affected by sex steroids, thyroid, and growth hormone (60).  BHMT activity has also been 
shown to be suppressed by triiodothyronine (55) and is likely affected by testosterone and 
estrogens, but much remains to be learned about the hormonal regulation of BHMT (65). 
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Transsulfuration 
 Transsulfuration is the irreversible catabolic pathway for homocysteine to cysteine 
and is specific to the liver, kidney, pancreas, intestine, and brain (1).  As the only reaction 
resulting in the catabolism of homocysteine, CBS has also been implicated in the regulation 
of plasma homocysteine concentrations.  The effect of CBS upregulation on serum 
homocysteine levels was investigated by Wang et al. (66) using a transgenic mouse model.  
By giving mice supplemental zinc, transcription of the CBS transgene under the regulation of 
the metallothionein promoter was stimulated, which resulted in increased CBS activity and 
expression in the liver and kidney with concurrently decreased serum homocysteine 
concentrations.  The homocysteine-lowering effect of CBS upregulation was also observed 
when mice were fed a high methionine-low folate diet, which successfully induced 
hyperhomocysteinemia in wild-type mice.  Conversely, mice that are completely deficient in 
CBS had plasma homocysteine concentrations 40-fold greater than their wild-type 
counterparts, whereas CBS activity decreased 50% and plasma homocysteine 
concentrations increased 2-fold in the heterozygotes (67).   
CBS and CGL are also subject to regulation, by diabetes as well as other hormones 
and cellular conditions.  CBS and CGL activities were elevated in the Ames dwarf mouse 
liver (53).  The effect of increased activities of these enzymes in the Ames dwarf mouse 
were studied further, which revealed increased flux through the transsulfuration pathway in 
the liver, kidney and brain, as well as lower plasma homocysteine concentrations (54).  CBS 
activity and transsulfuration flux are also enhanced in response to increased SAM 
concentrations (68) and under oxidative conditions (12).  This is likely due to the need for 
disposal of excess methionine and/or generation of cysteine, which can be used for the 
production of a variety of important intracellular metabolites, including the antioxidants 
glutathione and taurine.  Glutathione and taurine are involved in redox homeostasis and are 
considered a key defense against intracellular oxidation.  Cysteine is also a precursor to 
hydrogen sulfide, which is a transmitter with neurological, intestinal, and cardiovascular 
effects (69). 
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Methyl balance, homocysteine, and the SAM:SAH ratio 
Dietary methyl donors include methionine, folate, betaine, and choline.  Methionine is 
an essential, sulfur-containing amino acid found in dietary proteins.  Folate and betaine are 
utilized by the remethylation pathways for donation of methyl groups to homocysteine for 
regeneration of methionine.  Choline does not serve as a methyl donor directly, but it can be 
converted to betaine by the enzyme choline oxidase, also commonly referred to as choline 
dehydrogenase.  Varying dietary composition with respect to dietary methyl donors can 
perturb folate one-carbon, methyl group, and homocysteine metabolism. 
Methionine is metabolized to SAM, the primary methyl donor for transmethylation 
reactions and a positive regulator of transmethylation and transsulfuration reactions (1).  
Feeding rats high-methionine diets increased activities of MAT, GNMT, and SAHH (70,71).  
Transsulfuration enzymes were also upregulated, whereas MS was decreased (72).  BHMT 
was upregulated in response to low methionine diets and this effect was enhanced by 
betaine or choline supplementation (72,73).   
Diets deficient in one methyl donor illustrate the balance required between the 
pathways.  Low folate may disrupt the balance that normally results from the reciprocal 
regulation of GNMT and MTHFR.  In rats fed a folate-deficient diet, GNMT activity increased 
and the intracellular SAM:SAH ratio decreased in the liver and pancreas within just 2 weeks 
(74,75).  Folate or choline deficient diets are associated with hyperhomocysteinemia  and 
decreased concentrations of the provided methyl donor (i.e. choline deficiency results in 
lower hepatic folate concentrations), likely due to compensatory upregulation of the 
remethylation of homocysteine by the pathway utilizing the available methyl donor (76).  In 
humans, an acute dose of betaine (3 or 6 g) was sufficient to decrease plasma 
homocysteine concentration up to 10% in healthy middle-aged adults (77). 
Normal plasma homocysteine levels in humans range from 5-15 µmol/L (78).   Mild 
to moderate hyperhomocysteinemia is classified as plasma homocysteine levels between 15 
and 30 µmol/L, intermediate and severe hyperhomocysteinemia refers to plasma 
concentrations above 30 µmol/L and 100 µmol/L respectively.  Disruption of homocysteine 
metabolism, specifically hyperhomocysteinemia, has been associated with increased risk of 
cancer, cerebro- and cardiovascular disease, neurological disease, osteoporosis, pregnancy 
complications, and birth defects (78-82).  In the Hordaland Homocysteine Study of over 
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18,000 patients in Western Norway, lifestyle and dietary factors such as smoking, increased 
coffee consumption, and low folate intake were associated with hyperhomocysteinemia, 
whereas there was an inverse relationship between physical activity and plasma 
homocysteine concentrations (82).  Age, gender, renal function, and the MTHFR 677C>T 
polymorphism were also found to be key determinants of homocysteine levels.  Plasma 
homocysteine concentrations were increased in men and patients that were older, had 
elevated creatinine levels (an indicator of renal dysfunction), and/or the T/T genotype for 
MTHFR 677.  The MTHFR677C>T point mutation is particularly common, with prevalence of 
up to 20% in some populations, but polymorphic forms of GNMT, MS, SHMT, and CBS have 
also been identified (83,84).  This raises the possibility for nutrient-gene or gene-gene 
interaction effects and indeed, the response of homocysteine and folate one-carbon 
metabolism to folate has been shown to be affected by polymorphisms (83-85) and 
relationships with other methyl donors are likely to exist.  Inborn defects of methyl group and 
homocysteine metabolism have also been documented for all enzymes with the exception of 
BHMT and are associated with the accumulation of intermediate metabolites of their 
respective pathways (86).    
Dietary supplementation of B vitamins with the goal of lowering plasma 
homocysteine levels has been studied extensively and has been shown to be effective, but 
whether the lowering of homocysteine levels had protective effect against morbidity and 
mortality is still controversial (Williams and Schalinske, BioFactors, in press).  Early studies 
showed improved B-vitamin status lowered plasma homocysteine levels, and decreased 
incidence of adverse events or improvements in indicators of vascular endothelial 
dysfunction in patients treated with folic acid, B12, and/or B6 vs. those treated with a placebo 
(87-91).  However, these results have largely been refuted by the predominantly negative 
results of subsequent trials, including the NORVIT, WENBIT, HOPE-2, VISP, VITATOPS, 
and VITRO studies (92-102).   These studies generally had a mean follow-up time of several 
years and assessed a wide variety of vascular indicators and endpoints including carotid 
intima-media thickness and flow-mediated dilation (96), markers of arterial inflammation (93-
102), need for revascularization procedures (98), occurrence of thromboembolism (97,99), 
occurrence of stroke and myocardial infarction (92,94,98,100,101,103), as well as overall or 
coronary/vascular-related mortality (92,94,95,98,100,103).     
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It is not clear as to what factors may account for the disparity in these findings.  The 
duration of treatment, B-vitamin status, and polymorphisms of enzymes involved in 
homocysteine metabolism could potentially play a role.  Notably, the treatment period was 
generally longer in duration for the later studies in comparison to those conducted earlier, 
i.e. several years vs. weeks or months.  The apparent affect of the duration of treatment is 
supported by the meta-analysis by Potter et al (96) in which they found that in patients post-
stroke, B-vitamin treatment had positive effects in the short term, but these effects were not 
sustained long term.  Research in this area is ongoing and several recent short term studies 
have demonstrated benefits of folate supplementation alone on vascular outcomes in high-
risk patients (105-107)
. 
  Interestingly, the data suggests that improvements are independent 
of the homocysteine-lowering effect of treatment, therefore other mechanisms of action 
should also be considered for short-term treatment effects.
.
 More data is also expected from 
additional long-term studies of high-risk populations which have been initiated, but are not 
yet complete (108,109).  Although poor B-vitamin status and polymorphisms of MTHFR 
have been associated with elevations in plasma homocysteine levels and may impact the 
homocysteine-lowering response to treatment, there is little or no evidence to support that 
these factors may account for differential results between studies. 
Vascular diseases are not the only conditions in which there have been trials of B-
vitamin interventions.  There appears to be no effect of homocysteine-lowering B-vitamin 
therapy on Alzheimer’s disease and cognitive decline (110-112), and the results are 
conflicting regarding potential effects on bone mineral density and turnover, and fracture 
occurrence (113-115).  However, not all findings have been negative; the Women’s 
Antioxidant and Folic Acid Cardiovascular Study found that long-term daily treatment with 
folic acid, pyridoxine, and cobalamin in a high-risk population reduced the risk of age-related 
macular degeneration (116).  Furthermore, studies in healthy individuals suggest that 
treatment with B vitamins may be an effective means of reducing the risk of stroke (117) and 
slowing the progression of early-stage atherosclerosis (118).  Though the data is limited, the 
most important research area for the future use of treatments with the homocysteine-
lowering vitamins will be identifying specific populations that are most expected to benefit 
from therapy, with particular emphasis on primary prevention. 
Although homocysteine concentrations have been closely linked to the development 
of disease, some studies have suggested that SAH may be an even better biomarker (13-
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16).  Maintenance of the SAM:SAH ratio is critical because this ratio serves as an indicator 
of transmethylation potential.  Thus, important transmethylation reactions, such as the 
methylation of DNA and PE, are compromised when the SAM:SAH ratio is lowered (119-
122).  Hypomethylation of DNA was associated elevated SAH levels in particular.  
Conversely, elevated SAM levels in the brain of the PEMT knockout mouse were associated 
with hypermethylation of DNA and proteins (123).  As another contradiction between the two 
GNMT knockout models, the Chen group reported global DNA hypomethylation using the 
Methylamp Global DNA Methylation Kit from Epigentek (37), whereas the group of Wagner, 
Luka, and Mato found genomic DNA hypermethylation – as would be expected due to the 
greatly increased availability of SAM – as measured by high performance capillary 
electrophoresis (36).  In addition to the potential role of GNMT at the tissue level, interorgan 
metabolism of SAH may also help regulate whole body levels of SAH, thereby affecting the 
SAM:SAH balance.  Based on the arterio-venous differences across tissues, it has recently 
been shown that SAH is exported from the liver, whereas 40% of circulating SAH was 
removed by the kidney (124).  With physiological levels of plasma homocysteine and normal 
renal function, the kidney also removes a substantial amount of circulating homocysteine 
(20-50%) from the plasma, where the majority is metabolized rather than being excreted 
(125-127).  Furthermore, homocysteine uptake and metabolism in the healthy rat kidney 
increases in response to experimentally-induced hyperhomocysteinemia.   Clinically, there is 
a strong association between elevated homocysteine levels and increasing severity of renal 
disease (128) and transmethylation flux has been shown to be suppressed in diabetic 
patients with nephropathy (129).  Taken together, this suggests that adequate kidney 
function appears to be a critical component for homeostasis of the SAM:SAH ratio and 
homocysteine concentrations.  This also highlights the complexity of methyl group and 
homocysteine metabolism, and although each of the constituent pathways has been well-
studied, additional efforts need to be made towards the development of a more unified 
theory of regulation of methyl group and homocysteine metabolism.  This might be 
accomplished through a combination of techniques including mathematical modeling (130) 
and in vivo tracer kinetic studies (131). 
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Epigenetic regulation of gene expression 
 The term “epigenetics” was first introduced by Waddington in the early 1940’s (132). 
Waddington used the term to describe the interactions between the environment and genes 
that governed the development of cells.  Epigenetics remains an active field of investigation 
in developmental biology, but the concept has further evolved and the modern definition of 
epigenetics refers to heritable - mitotic and/or meiotic - changes in gene function that cannot 
be attributed to alterations of the sequence of bases (133).  Epigenetic mechanisms include 
DNA methylation, histone modifications, and chromatin remodeling.  These processes can 
be thought of as a level of regulation superimposed on the genome.  Although epigenetic 
marks are heritable, they have also been shown to be vulnerable to change by 
environmental influences.  Changes in epigenetic regulation are hallmarks of development, 
aging, and the pathology of many diseases.   
 DNA methylation is likely the most thoroughly studied epigenetic mechanism.  
Methylation of DNA serves many functions including contributions to genome stability, 
repression of parasitic elements, imprinting, X chromosome inactivation, and regulation of 
gene expression (8).   DNA is methylated at the 5'-position of cytosine bases within the 
context of CpG dinucleotides, which consist of a cytosine base linked to a guanine base by 
a phosphodiester bond.  Eighty percent of CpG dinucleotides are generally highly 
methylated and located in repetitive sequences and satellite DNA, whereas the other CpGs 
are found in dense clusters called CpG islands (8,134).  Methylated regions are typically 
associated with tightly condensed heterochromatin.  Alternatively, unmethylated CpGs are 
generally found in the more loosely packed euchromatin.  CpG islands are associated with 
over 50% of known genes and are defined by an overall GC content of >60% over the range 
of at least 200 bases, and are found upstream of genes in the promoter, untranslated 
region, or exon 1 (135).  Although under normal conditions most CpG islands are 
unmethylated, patterns of CpG methylation appear to be developmental stage- and tissue-
specific (134).  Aberrant global and CpG island DNA methylation has also been noted in the 
pathogenesis of diseases such cancer and cardiovascular disease (8,136).    
DNA methyltransferases are a family of enzymes involved in the establishment and 
maintenance of DNA methylation patterns via SAM-dependent transmethylation.  The de 
novo DNA methyltransferases that establish DNA methylation patterns are DNMT3a and 3b, 
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whereas DNMT 1 serves as the maintenance methyltransferase (137).  Reflecting their 
function, DNMT3a and 3b are most abundantly expressed in embryonic stem cells, but 
expression decreases with differentiation (138).  There is also a third member of the DNMT3 
family, DNMT3L, which is a regulatory factor that interacts with DNMT3a and 3b to enhance 
de novo methylation (103).  DNMT1 functions to maintain DNA methylation patterns during 
cellular replication.  As such, DNMT1 contains a replication foci targeting sequence, 
interacts with the transcriptional machinery, and the methyl-DNA-binding site favors 
hemimethylated DNA (137,140). 
 Most DNA does not exist freely in the nucleus.  Rather, it is wrapped around an 
octomer of histones, forming nucleosomes, and then is further condensed into the higher 
order structure of chromatin.  There are extensive and complex interactions between DNA 
methylation, histone modifications, and chromatin remodeling that affects the structure of 
DNA, which in turn is related to genomic stability and regulation of gene expression (141-
143).  The proteins that help bridge the gap between DNA methylation and the formation of 
heterochromatin are the family of methyl-CpG-binding domain (MBD) proteins (141).  The 
MBD family consists of MBD1-4 and methyl-CpG-binding protein 2 (MeCP2).  In addition to 
the common MBD, all MBD proteins have been shown to be capable of mediating 
transcriptional repression, primarily through the recruitment of other regulatory proteins that 
reinforce the DNA methylation signal with histone modifications and chromatin remodeling.  
MBD1 interacts with the SET and Suv histone methyltransferases.  MBD2 and MBD3 are 
part of the mi-2/NuRD chromatin remodeling complex.  Within this complex, MBD2 appears 
to help target the methylated sequences on DNA, whereas MBD3 contains a loss-of-function 
mutation in the MBD and facilitates protein-protein interactions.  MBD4 is unusual because 
its most well-studied function is as a DNA repair enzyme, with particular affinity for TpG-CpG 
mismatches.  Lastly, MeCP2 links DNA methylation to repressive chromatin conformation by 
recruitment of histone deacetylases and histone methyltransferases.  MeCP2 may also be 
involved in the regulation of splicing.   
There are numerous post-translational modifications of histones, including 
acetylation, methylation, phosphorylation, ubiquitination, and biotinylation (144,145).  
Histone acetylation is particularly dynamic, is controlled by histone acetyltransferases and 
deacetylases, and is generally associated with active regions of the genome (144).  Histone 
mono-, di-, or tri-methylation is more stable and these marks have been associated with 
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either transcriptional activation or repression.  Histone modification by phosphorylation, 
ubiquitination or biotinylation has not been studied as extensively as the acetylation and 
methylation marks.  Phosphorylation appears to play a role in transcriptional activation and 
chromosome condensation/segregation during mitosis.  Ubiquitination and biotinylation are 
involved in X chromosome inactivation and repression of transposable elements 
respectively (145).  There is a great deal of interplay between the histone modifications, the 
observation of which led to the development of the “histone code” hypothesis (146) which 
postulates that combinations of histone modifications could be used to predict the regulatory 
effect on the gene.  However, the concept of epigenetics is continuously evolving and 
gaining in complexity.  More recently discovered epigenetic mechanisms such as the 
involvement of noncoding RNAs are active areas of research (147). 
Evidence from studies of monozygotic twins shows that during early childhood, twins 
have similar patterns of DNA methylation and histone acetylation, but these similarities are 
lost in older twins (148).  These differences that accumulate over a lifetime might be 
attributed to environmental factors, including diet, which have been shown to impact 
epigenetic mechanisms.  The effects of methyl-deficient diets have been particularly well-
studied in the context of HCC (149).  Feeding of methyl-deficient diets to rats resulted in 
perturbations of folate metabolism, thereby compromising thymidylate and purine synthesis 
and increasing uracil misincorporation, abasic sites and DNA strand breaks.  These 
phenomena are thought to precede increased DNMT activity, altered expression patterns of 
DNMTs and MBDs, and abnormal histone modification patterns (150-154).  The effects of 
methyl deficiency on DNA methylation were specific to the liver (153) and were reversible for 
at least 9 weeks, but not 18 weeks after initiation of the diet by treating with a methyl-replete 
diet (154), suggesting a possible window for dietary interventions.   In a similar fashion, 
folate deficiency decreases the SAM:SAH ratio and is associated with global and gene-
specific DNA hypomethylation in both rodent models and human subjects (74,75,155,156). 
This effect is reversible with folate supplementation, at least in the short term (155).  Folate 
treatment has also been shown to restore DNA methylation levels to normal in lymphocytes 
of hemodialysis patients with hyperhomocysteinemia and in livers of aging rats (156,157).  
Genes of methyl group and homocysteine metabolism have also been implicated in nutrient-
gene interactions affecting epigenetic mechanisms (83).  In addition to methyl donors, 
bioactive food components, zinc, selenium, and retinoic acid are all potential modulators of 
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epigenetic regulation via effects on methyl group and homocysteine metabolism or 
epigenetic regulatory proteins (158). 
For the studies presented herein, genomic and CpG island DNA methylation, as well 
as expression of DNMTs and MBDs were used as indicators of epigenetic regulatory 
processes.  DNA methylation status was measured by digestion of DNA with methylation-
specific restriction enzymes followed by cytosine extension assay and expression of 
epigenetic regulatory proteins was determined primarily by real time reverse-transcriptase 
PCR for relative quantification of mRNA abundance.  These methods are well-accepted and 
have been used previously for the assessment of epigenetic dysregulation (151,153,154), 
though our laboratory has made minor modifications (detailed in Materials and Methods 
section within each appropriate chapter).  These analyses will detect overall changes in the 
degree of genomic and CpG island DNA methylation, as well as relative expression of the 
DNMTs and MBDs.  DNA methylation patterns may also be assessed at specific genes and 
we expect that this will be the goal of future studies. 
  
Altered methyl group and homocysteine metabolism including epigenetic regulation 
There are numerous factors that can disrupt normal methyl group and homocysteine 
metabolism.  As has been previously discussed herein, these factors include dietary intake 
and nutritional status, genetic contributions, environmental or pharmacological exposures, 
and hormonal balance.  The majority of the research presented in the remainder of this 
document is focused on the effects of retinoids and a diabetic condition on methyl group and 
homocysteine metabolism, including epigenetic regulation of DNA via methylation.  
Therefore, it is important to review basic concepts related to the function of retinoids and the 
pathology of diabetes, as well as to examine the current literature describing interactions 
between retinoids or a diabetic condition and metabolic and epigenetic aberrations. 
 
Retinoids  
Retinoids comprise the vitamin A family of compounds including retinyl esters, 
retinal, retinol, and retinoic acid.  Retinal is used in the visual cycle, but for all other 
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purposes, retinoic acid is the biologically active form.  Retinoic acid is a ligand for the 
retinoic acid receptor (RAR).  The retinoic acid-RAR complex then dimerizes with the 
retinoid x receptor.  This heterodimer recognizes the canonical retinoic acid response 
elements (RAREs) in the promoter regions of genes, thereby stimulating transcription.  The 
pleiotropic effect of vitamin A may be attributed to the presence of RAREs in the promoter 
region of genes for several transcription factors which can explain the diverse necessity of 
vitamin A for cellular differentiation, and optimal reproductive and immune function (159).  
 Retinoids are widely used in cancer prevention and treatment (159,160), as well as 
for dermatological disorders such as acne, rosacea, and psoriasis (160).  Despite 
widespread use, there still remain concerns regarding the toxicity of retinoids, thus 
necessitating further investigation.  Retinoic acid is absorbed, transported, and metabolized 
differently than other forms of vitamin A, such as retinol or carotenoids (161,162).  Retinoic 
acid is rapidly absorbed and is bound by albumin during transport to the liver by the portal 
vein, rather than via the traditional absorption and transport of fat-soluble vitamins by 
chylomicrons and entrance to the lymphatic circulation prior to entering the bloodstream.  
Furthermore, the half-life of all-trans-retinoic acid in plasma is <1 hr in both rodents and 
humans, and retinoic acid is not stored in the liver or extrahepatic tissues (161,163), though 
it does alter vitamin A metabolism by increasing expression of lecithin:retinol acytransferase, 
which esterifies retinol to retinyl esters for storage (164,165).  Intracellular retinoic acid may 
be bound to its associated receptors for biological activity, bound by cellular retinoic acid-
binding protein, or catabolized (166).  The catabolism of retinoic acid to 4-oxoretinoic acid or 
retinoyl β-glucuronide is catalyzed by cytochrome P450 enzymes, which can be upregulated 
in response to retinoic acid (164,167).  Although this regulatory effect suggests maintenance 
of vitamin A homeostasis, all-trans-retinoic acid is more biologically active and appears to be 
more toxic than other retinoids (163,166).  Hypervitaminosis A presents with nausea, 
vomiting, fatigue, headache, dermal irritation, skeletal pain, and hepatotoxicity, including 
elevated serum AST and ALT activity, lipid accumulation, fibrosis, and cirrhosis if left 
untreated (163,168). Vitamin A toxicity is generally treated simply by halting excess vitamin 
A intake and addressing conditions which may predispose individuals to toxic effects such 
as excessive intake of ethanol or of other fat-soluble vitamins, protein malnutrition, and pre-
existing liver or renal disease (161,168). 
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We have shown that treatment of rats with excess vitamin A at pharmacological 
doses results in abnormal methyl group and homocysteine metabolism, perturbation of SAM 
and SAH levels, and DNA hypomethylation (169-171).  Rats treated with vitamin A in the 
form of retinyl palmitate, cis-retinoic acid, or all-trans-retinoic acid (RA) had elevated hepatic 
GNMT activity and abundance (47,48,169-171).  This effect appears to be specific to the 
liver, with no changes in GNMT activity and/or abundance observed in the pancreas or 
kidney (47).  The hepatic induction of GNMT was most dramatic in the RA-treated rats, 
which also exhibited DNA hypomethylation as measured by the SssI methyl-acceptance 
assay (170).  The results of this study have also been replicated in a cell culture model of 
somatic bovine cells, in which treatment with RA resulted in relative demethylation of DNA 
(172).  The induction of GNMT and DNA hypomethylation were accompanied by increased 
expression of Oct4, a marker of pluripotency, compared to control cells, thereby indicating 
deregulation of differentiation.  It is also of importance to note that RA treatment in the rat at 
therapeutic doses was also sufficient for induction of hepatic GNMT, though DNA 
methylation status was not assessed in that particular study (171). 
Mechanistically, the increase in GNMT activity is likely mediated by the effect of 
retinoids on hepatic folate metabolism.  MTHFR activity was suppressed in rats fed a diet 
high in retinyl acetate or retinyl palmitate, thereby decreasing 5-CH3-THF levels, presumably 
relieving the allosteric inhibition of GNMT by 5-CH3-THF (173).  RA treatment has also been 
shown to increase hepatic MS activity (55,171).  However, RA treatment was without effect 
on PEMT, BHMT, and CBS (48,50,55).  The impact of these perturbations on plasma 
homocysteine and glutathione levels was varied, generally lowering or leaving plasma 
homocysteine concentrations unchanged.  Plasma homocysteine and glutathione levels 
were unaffected by retinoid treatment alone (169,170), with one report of homocysteine 
levels markedly decreased by 10 d of high-dose retinoid treatment (171).  RA treatment has 
also been shown to interact with other factors perturbing methyl group metabolism, such as 
hypo- or hyperthyroidism and diabetes (48,51,55).  
There are few reports of the effects of retinoid treatment on DNA methylation status.  
Retinoic acid is also known to be teratogenic with central nervous system, ear, eye, and 
craniofacial abnormalities being the most common developmental effects (160,166).  In 
mice, the treatment of dams with RA during pregnancy resulted in DNA hypomethylation of 
both genomic and CpG island DNA within the palate of the affected offspring (174).  In the 
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treatment of cancer, retinoids are used as differentiation therapy.  This effect has been 
studied in cancerous and embryonic stem cells models and is proposed to be due in part to 
epigenetic regulation of imprinted genes and genes for telomerase and cellular regulatory 
factors (175-177).  Interestingly, evidence from acute promyelocytic leukemia cell lines and 
blasts from patients, it appears that effects on epigenetic regulation may be mediated in part 
by direct downregulation of the expression of DNMTs by RA (178).  The effect of RA therapy 
on DNA methylation has not been explored in the normal liver in rodents or humans.    
 
Diabetes 
Diabetes mellitus affects approximately 12% of the U.S. population and data 
suggests that the incidence rate will continue to rise in the U.S. and worldwide over the next 
several years (179).  It is estimated that ninety-five percent of cases are type 2, while the 
remaining 5% are type 1.  Though both types of diabetes are characterized by altered 
glucose metabolism and hyperglycemia, the pathologies of the diseases are different.  Type 
1 diabetes, often called insulin dependent diabetes mellitus, results from the loss of insulin-
producing pancreatic β-cells and consequently, a lack of insulin.  Although the mechanisms 
responsible for β-cell destruction are not entirely clear, in most cases it is proposed to be the 
result of an autoimmune response that has been associated with exposures to particular 
viruses and a genetic predisposition (180).  Type 1 diabetic patients tend to develop the 
disease early in life, which is why it has also been called childhood-onset diabetes.  Type 2 
diabetes had traditionally been thought of as adult-onset diabetes, but is becoming more 
prevalent in children and adolescents (179).  Type 2 diabetes, which is also known as non-
insulin dependent diabetes mellitus, is characterized by insulin resistance in which the cells 
do not respond appropriately to insulin despite hyperinsulinemia (181,182).  Insulin 
resistance is proposed to develop from lipid overload, abnormal lipid metabolism, and 
chronic inflammation (183).  Over time, many type 2 diabetics also develop beta cell 
dysfunction and impaired insulin secretion.  The pathogenesis of type 2 diabetes is believed 
to originate from a combination of genetic and lifestyle factors.  Type 2 diabetes is often 
clustered with the characteristics of metabolic syndrome, which includes abdominal obesity, 
elevated serum triglycerides and/or depressed HDL-C, hypertension, and hyperglycemia or 
insulin resistance (184).  Notably, both types of diabetes are also associated with the 
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development of secondary complications including macrovascular (i.e. cardiovascular 
disease, coronary heart disease, stroke) and microvascular (i.e. nephropathy, neuropathy, 
retinopathy) diseases (179,182).  Physiologically, both type 1 and 2 diabetic conditions are 
also characterized by hyperglycemia and a relative excess of glucocorticoids compared to 
insulin, whether based on actual concentrations or due to tissue insensitivity.   
The rat models of both type 1 and type 2 diabetes used in our studies are well-
characterized and closely resemble the condition of human patients.  Streptozotocin (STZ) 
is used to induce a type 1 diabetic state, in part by producing an autoimmune response 
against the pancreatic beta cells, similar to that observed in human type 1 diabetes (185).  
Following STZ injection, symptoms of diabetes such as hyperglycemia, hyperphagia, 
polyuria, and failure to gain or maintain weight manifest within days (186).  For our type 2 
model, we utilized the Zucker diabetic fatty (ZDF) rat which contains a mutation in the Lepr 
gene, which encodes for the leptin receptor (187).  This mutation results in an inability for 
proper interaction between leptin and leptin receptor, thereby abrogating the suppressive 
effect of leptin on appetite and insulin secretion.  In this way, the pathogenesis of the ZDF 
rat closely resembles the human type 2 diabetic condition with hyperinsulinemia, 
progressing to hyperglycemia and eventual beta cell failure.  Hyperinsulinemia is observed 
very early in life, the initial rise in blood glucose occurs between 7 and 8 weeks of age, with 
a frank diabetic condition presenting by 12 weeks, and beta cell failure occurring between 
22 and 42 weeks in male ZDF rats (188).  Both animal models are well-established and 
have been used extensively for the study of diabetes-associated dyslipidemia (189,190), 
atherosclerosis (191), abnormal vascular response (188,192), nephropathy (186,193,194), 
retinopathy (195,196), and neuropathy (197,198).  However, it may be noted that the STZ-
induced model of diabetes exhibits more moderate renal dysfunction than some other 
models of type 1 diabetes (186), such as the nonobese diabetic mouse, which we have 
used in subsequent studies.    
Perturbations of hepatic methyl group and homocysteine metabolism, as well as the 
net effect on plasma homocysteine levels, in an early diabetic condition has been well 
characterized in rodents (Figure 2).  Upregulation of transmethylation has been observed in 
both rodent models and human patients.  GNMT and PEMT are upregulated by 
glucocorticoids, STZ- and alloxan-induced type 1 diabetes (32,48-50).  Treatment of rats or  
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(199) and early type 2 diabetes (52).  In contrast, the effect of a diabetic condition on BHMT 
is consistent and well-characterized.  BHMT mRNA expression and/or activity were 
increased in diabetic rats and in hepatoma cells treated with glucocorticoids (48-50,52,200); 
this effect was reversed or attenuated with treatment by insulin in the STZ-induced diabetic 
model (200).  Hepatic CBS and CGL activities were increased in both glucagon-treated, as 
well as STZ-diabetic and ZDF rats (48,52,126,201).  CBS mRNA abundance was also 
increased in glucocorticoid-treated hepatoma cells (201). Insulin abrogated the increases in 
CBS activity (201,126). The effects of STZ-diabetes and insulin treatment were also 
observed at the transcriptional level as evidenced by similar changes in CBS mRNA (201).   
There have been very few studies of methyl group and homocysteine metabolism in 
the diabetic kidney.  House et al (126) reported a lack of effect of either glucagon treatment 
or STZ-diabetes, whereas Jacobs et al (199) reported that renal MS and MTHFR activities 
were suppressed by a type 1 diabetic condition.  Methyl group and homocysteine 
metabolism have not be investigated in the kidney of the ZDF rat.  Thus, all changes 
discussed thus far were observed in the liver and in an early diabetic condition (i.e. within 10 
d of onset).  The net effect of these perturbations results in lowered plasma homocysteine 
levels (48-52).  Early in the course of type 1 diabetes, diabetic patients also have been 
found to have lower fasting and post-methionine load plasma homocysteine concentrations 
relative to healthy controls (202).  However, in advanced diabetes it has been shown that 
MTHFR activity was suppressed in lymphocytes of diabetic patients (128) and both hepatic 
transmethylation and transsulfuration flux were decreased in diabetic nephropathy (129).  
This occurrence of metabolic disturbance in advanced diabetes, concurrent with the 
development of hyperhomocysteinemia in diabetic nephropathy (128,203) suggests the 
need to study the chronic diabetic condition, with particular attention to the influence of both 
the liver and the kidney. 
 Recently, diabetes has also been associated with alterations of epigenetic 
mechanisms, specifically histone modifications.  These studies of both cell culture and 
mouse models of hyperglycemia or diabetes have identified pathways or categories of 
genes with altered patterns of histone methylation.  The targets of this regulation include 
proteins involved in signal transduction, oxidative stress, immune function, and inflammatory 
pathways (204-208).  These effects were maintained even after the restoration of 
normoglycemia, suggesting a “metabolic memory” (204-206) which should be characteristic 
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of true epigenetic regulation.  The alterations of histone modifications were also cell-type 
specific (207,208).  This highlights the need for study of epigenetic regulation in the tissue of 
interest whenever possible.  Efforts should also be made to profile DNA methylation status 
of genome to complement this knowledge of histone modifications. 
Our long-range goal is to understand how diabetes-mediated alterations in metabolic 
processes may serve as a link to the numerous complications associated with diabetes, and 
how dietary intervention can prevent these adverse effects.  The focus of the studies 
presented here was on perturbations of key enzymes and metabolites of methyl group and 
homocysteine metabolism that occur in both type 1 and type 2 diabetes, and how these 
changes may be linked to alterations of epigenetic regulation.  To date, most studies have 
assessed only hepatic metabolism in the early diabetic condition and epigenetic regulation 
in diabetes has not been fully addressed within tissues of interest.  This includes the liver, 
kidney, and heart as tissues which contain the full complement of methyl group and 
homocysteine metabolic pathways and/or are affected by the secondary pathologies of 
diabetes.  Lack of such knowledge is an important problem, because understanding the 
metabolic link between these processes is essential for establishing dietary 
recommendations for preventing metabolic and epigenetic aberrations which may be related 
to secondary complications of diabetes, a major focal point for future research. 
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CHAPTER 3: Long-term, thrice-weekly supplementation with retinoic acid alters 
methyl group metabolism, but does not induce changes in DNA methylation status in 
rat liver 
A manuscript to be submitted to Hepatology. 
Kelly T. Williams and Kevin L. Schalinske 
 
Abstract 
S-adenosyl methionine-dependent transmethylation reactions are important in many 
biosynthetic and regulatory processes such that compromised methyl group availability 
results in a number of pathologies.  For example, global DNA hypomethylation is associated 
with genomic instability and overexpression of genes.  Glycine N-methyltransferase is a key 
protein in the regulation of methyl group supply and utilization; thus, it is important to 
understand how nutritional and/or hormonal factors influence GNMT.  Previously it has been 
demonstrated that administration of all-trans-retinoic acid (RA) rapidly induces glycine N-
methyltransferase and global DNA hypomethylation during short-term (7-d) studies.  The 
aim of this study was to investigate the long-term effects of RA administration on GNMT 
expression, DNA methylation, and hepatotoxicity.  Rats were treated orally with either 0, 5, 
or 30 µmol RA/kg body weight three times per week for a total of 2, 4, 8, 16, or 24 wk.  
Treatment with either dose of RA induced GNMT activity and abundance at 2 wk, and this 
increase was observed at all timepoints in the study.  Serum activities of alanine 
aminotransferase and aspartate aminotransferase were not affected by RA treatment.  
Interestingly, RA treatment resulted in significantly decreased hematocrit levels, as well as 
lowered plasma glutathione concentrations.  Chronic administration of RA results in a 
sustained increase in GNMT activity and protein abundance with little indication of 
hepatotoxicity and no effect on DNA methylation status. However, chronic administration of 
retinoic acid, even at therapeutic levels, can adversely impact hematopoiesis and 
antioxidant defense. 
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Introduction  
 Folate-dependent one-carbon metabolism is central to a number of biochemical 
processes including the biosynthesis of nucleic acids and the regeneration of methionine 
from homocysteine by methionine synthase (MS) (1).  The methyl donor for the MS reaction 
is 5-methyltetrahydrofolate (5-CH3-THF), which is synthesized by methylenetetrahydrofolate 
reductase (MTHFR) from 5,10-methylenetetrahydrofolate (5,10-CH2-THF).  The products of 
the MS reaction are methionine and tetrahydrofolate, which can be recycled back into the 
folate pool.  Methionine can be activated to S-adenosylmethionine (SAM), which serves as a 
methyl group donor for more than 100 different SAM-dependent transmethylation reactions 
(2,3).  Methyltransferases catalyze the transfer of a methyl group from SAM to a methyl 
acceptor molecule, which may include proteins, lipids, nucleic acids or other small 
molecules, thereby generating a methylated product and S-adenosylhomocysteine (SAH), 
which can subsequently be metabolized to homocysteine.  Most SAM-dependent 
methyltransferases are inhibited by SAH, therefore the SAM:SAH ratio is purported to be an 
indicator of transmethylation potential.   
Glycine N-methyltransferase (GNMT) is highly abundant in liver (1-3% of cytosolic 
protein) and is a proposed regulator of hepatic methyl group supply and utilization (2,4). The 
reaction catalyzed by GNMT involves the transfer of a methyl group from SAM to glycine, 
thereby forming sarcosine, a product for which the physiological function is unclear.  The 
regulation of GNMT is unique in that it is inhibited by SAH to a lesser extent than most other 
methyltransferases and is intricately tied to one-carbon folate metabolism (Figure 1).  
GNMT is allosterically inhibited by 5-CH3-THF (5), whereas MTHFR activity is suppressed 
by SAM (6).  Therefore, when methyl group supply is high, SAM concentrations are elevated 
and MTHFR activity is inhibited, decreasing the synthesis of 5-CH3-THF and relieving 
inhibition of GNMT.  Increased GNMT activity would be expected to decrease SAM levels, 
thereby restoring the SAM:SAH ratio.  Conversely, when methyl supply is low, SAM levels 
would also be decreased, relieving the inhibition of MTHFR, increasing 5-CH3-THF 
concentrations and inhibiting GNMT, thereby conserving methyl groups.  Taken together 
with recent reports that the SAM:SAH ratio is elevated up to 100-fold in two newly 
developed GNMT knockout mouse models (7,8), there is strong evidence for the role of 
GNMT in the regulation of transmethylation potential.  Given this critical regulatory role, it is  
  
 
important to gain a greater understanding of how nutritional or 
influence GNMT expression and activity.
Retinoid compounds are widely used as t
in cancer prevention and treatment (9,10)
daily doses of retinoid compounds can alter 
metabolism, in part by the induction of GNMT.  
protein abundance increases in 
acid or all-trans-retinoic acid (RA)
pharmacological factors may 
 
herapies for dermatological conditions and 
.  It has previously been demonstrated that large 
folate one-carbon and methyl group 
We have shown that GNMT activity and 
response to treatment with retinyl palmitate, 9
 (11-13).  RA was the most potent inducer of GNMT
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also resulted in significant DNA hypomethylation during short-term studies (7-d), suggesting 
that the induction of GNMT compromises methyl group availability for other SAM-dependent 
transmethylation reactions (13).  It has long been known that the reduction of methyl group 
availability by chronic feeding of a methyl-deficient diet results in global and gene-specific 
DNA hypomethylation, which is associated with genomic instability and overexpression of 
genes, specifically the proto-oncogenes c-myc, c-fos, and c-ras (14-16).  The long-term 
adverse effects of a methyl deficient diet are an independent cause of liver fibrosis, 
cirrhosis, and hepatocellular carcinoma.  Hepatotoxicity is also a potential side effect of 
retinoids, with increased serum ALT and AST activity reported in up to 33% of patients (10).  
Although the impact of short-term retinoid treatment on methyl group metabolism is well-
characterized, data are lacking for effects  of retinoid administration after several months, 
which is the usual duration of therapeutic treatments.  Therefore, the aim of the current 
study was to investigate the long-term effects of RA administration on GNMT expression, 
DNA methylation and hepatotoxicity 
 
Materials and Methods 
Chemicals and reagents  Reagents were obtained as follows:  2,4-dinitrophenylhydrazine, 
RA, Sigma-Aldrich Chemical Co. (St Louis, MO); Coomassie Plus Protein Reagent, Pierce 
Chemical; enhanced chemiluminescence Western blotting detection reagents, Amersham 
Biosciences; goat anti-mouse horseradish peroxidase secondary antibody Southern 
Biotechnology (Birmingham, AL); phenylmethylsulfonyl fluoride (PMSF), Calbiochem; S-
adenosyl-L-[methyl-3H] methionine, New England Nuclear (Boston, MA).  GNMT antibodies 
were provided by Yi-Ming Chen, National Yang-Ming University, Taipei, Taiwan (17).  All 
other chemicals and reagents were of analytical grade. 
 
Animals  All animal protocols were approved by and conducted in accordance with the 
guidelines set forth by the Iowa State University Institutional Animal Care and Use 
Committee.  Male Sprague-Dawley rats (50-75 g at onset) were housed in individual cages 
with a 12:12 hr light:dark cycle, and given free access to water and semi-purified diet as 
previously described (11).  Rats were randomly assigned to a treatment dose and duration 
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(n= 5-6 per group, 72 animals total).  The treatment regimen consisted of 0, 5, or 30 µmol 
RA/kg body weight (control, low RA, high RA) administered orally in corn oil vehicle three 
times per week for a total of 2, 4, 8, 16, or 24 wk.  Treatment doses were chosen based on 
the normal dosages for retinoid therapies and based on previous dose-response studies 
demonstrating that the greatest induction of GNMT was with a dose of 30 µmol/kg body 
weight (18).  The 5 µmol/kg body weight dose is equivalent to 1.5 mg/kg body weight; 
treatment for dermatological conditions is usually prescribed at 0.5-2 mg/kg body weight/d 
for 6 months (19).  Treatment protocol was designed to minimize dermatological irritation. 
All treatments were initiated immediately after an acclimation period and rats were 
euthanized at the end of the each treatment period.  Animals were anesthetized by 
intraperitoneal injection with ketamine and xylazine (90 and 10 mg/kg respectively), 
heparinized whole blood samples were collected by cardiac puncture, and livers were 
rapidly excised.  An aliquot of whole blood was collected in hematocrit capillary tubes, 
sealed, and percent hematocrit was determined after centrifugation for 5 min in an Autocrit 
Ultra 3 Microhematocrit Centrifuge (BD Diagnostics, Franklin Lakes, NJ).  A portion of the 
liver was immediately homogenized and cytosolic extracts prepared as previously described 
(20,21); the remainder was snap frozen in liquid nitrogen and subsequently stored at -70°C. 
 
GNMT activity and abundance  GNMT activity was determined based on the method of 
Cook and Wagner (22) with minor modifications (11).  Briefly, 250 µg protein was added to a 
reaction mixture of 0.2 mol/L Tris buffer (pH 9.0), 5 mmol/L dithiothreitol, 2 mmol/L glycine, 
and 0.2 mmol/L S-adenosyl-L-[methyl-3H]methionine and incubated at 25°C for 30 min.  
Reaction was stopped by addition of 10% trichloroacetic acid and unreacted SAM was 
removed by addition of activated charcoal and centrifugation.  Aliquots of supernatant were 
used for liquid scintillation counting.  GNMT abundance was assessed using immunoblotting 
and subsequent chemiluminescent detection as described previously (20).  SigmaGel 
Software (SPSS, Chicago, IL) was used for densitometric analysis of relative abundance.  
 
Plasma homocysteine and glutathione Plasma samples were derivatized for 
determination of plasma homocysteine and glutathione as described by Ubbink et al (23) 
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with minor modifications (24).  Homocysteine and glutathione were analyzed by HPLC with 
fluorometric detection by injecting 100 µL of sample onto a µBondapak C18 Radial-Pak 
column (Waters, Milford, MA) using a mobile phase of 40 mL/L acetonitrile in 0.1 mol/L 
potassium phosphate buffer (pH 2.1).  N-acetylcysteine (1 mmol/L) was used as an internal 
standard. 
 
DNA methylation  Genomic DNA was isolated from snap frozen tissue using a commercial 
kit (cat # A1125, Promega).  Global and CpG island DNA methylation status was determined 
by the method of Progribny et al (25) and as described previously (21).  Briefly, 1 µg DNA 
was digested with the methylation-sensitive restriction enzymes HpaII and BssHII – for 
assessment of global and CpG island DNA methylation respectively, followed by cytosine 
extension assay with Amplitaq DNA Polymerase (Applied Biosystems), and [3H]-dCTP.  
After samples were applied to Whatman anion exchange paper, washed in 0.5 mol/L sodium 
phosphate buffer, and dried, liquid scintillation counting was utilized for determination of 3H 
incorporation.  
 
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activity  
Plasma levels of ALT and AST activity were determined using the Reitman-Frankel method 
(26) with minor modifications.  Briefly, 100 µL of plasma was added to 500 µL substrate mix 
and incubated at 37˚C for 30 min or 1 hr for ALT and AST assays, respectively.  The 
substrate mix consisted of 0.1 mol/L sodium-potassium phosphate buffer (pH 7.4), 2 mmol/L 
α-ketoglutarate, and 200 mmol/L alanine or aspartate for assessment of ALT or AST 
respectively.  Following incubation, 500 µL of a color reagent containing 0.1 mol/L 2,4-
dinitrophenylhydrazine in 1 mol/L HCl was added to all samples, which were then incubated 
at room temperature for 20 min.  Absorbance was measured on a spectrophotometer at 510 
nm and compared to a standard curve for determination of ALT and AST activity.    
 
Statistical analysis  For each timepoint, data for each treatment group were subjected to a 
one-way ANOVA followed by Fisher’s least significant difference test for multiple 
comparisons (SigmaStat, SPSS, Chicago, IL).  When equal variance or normality tests 
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failed, the ANOVA on ranks procedure was utilized.  Data from all timepoints were analyzed 
by two-way ANOVA followed by Fisher’s least significant difference test for multiple 
comparisons to test for effects of time, RA treatment, or time x treatment interactions. 
Differences were considered significant at P < 0.05; trends were noted at 0.05 < P < 0.1. 
 
Results 
Induction of GNMT by long term thrice-weekly RA treatment   
Elevation of GNMT activity by administration of RA was observed at all measured 
timepoints, with the exception of 4 wk (Figure 2A).  The increases in GNMT activity were 
generally associated with increases in GNMT abundance, which were observed at all 
timepoints (Figure 2B).  Consistent with our previous short-term studies (18), RA 
administration resulted in the elevations of GNMT activity and abundance in a dose-
dependent manner.  Moreover, this effect was also observed at both early and late 
timepoints in this study of RA treatment. 
 
RA treatment had no effect on DNA methylation status   
As measured by the method of Pogribny et al (25), an increase in [3H]-dCTP 
incorporation into DNA digested by methylation-specific restriction enzymes indicates 
hypomethylation, whereas a decrease indicates hypermethylation.  However, there were no 
observed differences in [3H]-dCTP incorporation between treatment groups at 2 or 24 wk 
whether the DNA was digested with HpaII or BssHII (Table 1).  This signifies that there were 
no overall changes in global or CpG island DNA methylation status. 
 
Indicators of hepatotoxicity were minimally affected by RA treatment   
RA treatment had no effect on rat weight or weight gain between groups at each 
respective timepoint (Table 2).  Likewise, there was no evidence of RA-induced 
hepatomegaly based on a lack of effect of RA administration on relative liver weight (Table 
2).  However, when all data was subjected to a two way ANOVA, in addition to the 
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Figure 2.  RA treatment of rats at 5 or 30 µmol/kg body weight increases GNMT activity 
and/or abundance in a dose-dependent manner.  (A)  Hepatic GNMT activity levels and  (B)  
hepatic GNMT protein levels relative to the control, data are means ± SEM, different letters 
denote a significant difference between groups within that timepoint, p < 0.05. 
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significant effects of time (p < 0.001), as would be expected due to growth of the animals, 
there were also slight trends towards decreased body weight (p = 0.062) and weight gain (p 
= 0.098), as well as increased relative liver weight (p = 0.097) associated with RA treatment.  
Plasma ALT and AST activity levels at 24 wk were also used as biomarkers of 
hepatotoxicity.  Activities of these enzymes are high in liver, but normally low in plasma, 
therefore ALT and AST activities are only high in plasma when damage to the liver results in 
release of the enzymes into the circulation.  There were no significant differences observed 
in plasma ALT or AST activity at 24 wk (Table 3), indicating a lack of hepatotoxicity. 
 
Long term RA treatment decreased plasma glutathione concentrations. 
RA treatment did not have a significant effect on plasma homocysteine levels at any 
of the individual timepoints assessed.  However, two-way ANOVA revealed a trend towards 
a decrease in homocysteine with RA treatment (p = 0.073, representative data from 24 wk 
shown in Table 3).  At 24 wk, glutathione levels were found to be decreased by 28% in 
animals receiving the high RA treatment compared to the control group (p = 0.013).  The 
plasma glutathione concentration was also 11% lower in low RA vs. controls, though this 
difference did not attain significance (p = 0.103).  There were no differences in glutathione 
levels between treatment groups detected at earlier timepoints or by two-way ANOVA 
analysis (data not shown). 
 
Hematocrit levels are decreased by long-term RA administration  
Given the well-established interaction between vitamin A and iron metabolism, as 
well as the role of vitamin A status on cellular differentiation, hematocrit levels were 
determined as a measure that would be sensitive to either of these effects.  There were no 
changes observed in hematocrit levels at 2 wk, but beginning at 4 wk hematocrit levels were 
lower in RA-treated rats compared to control animals (Figure 3).  In general, this decrease 
in hematocrit was observed in all rats receiving RA, and two-way ANOVA revealed a 
significant effects of RA, time, and a treatment by time interaction (p < 0.001). 
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Figure 3.  Hematocrit levels are decreased by RA treatment. Data are means ± SEM (n = 5-
6).  Different letters within a time indicate a significant difference between group means, p < 
0.05.  
 
Discussion 
 Homeostasis of methyl group and one-carbon metabolism are essential for many 
processes fundamental to health due to involvement in cellular growth and differentiation, as 
well as methylation of critical cell components.  Although short-term effects of RA treatment 
on hepatic methyl group and homocysteine metabolism have been established, chronic 
effects have yet to be fully investigated.  In this study, we found that long-term thrice-weekly 
RA administration resulted in sustained induction of hepatic GNMT activity, but was without 
effect on DNA methylation status.  There were minimal to no signs of hepatotoxicity, but 
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decreased plasma glutathione and markedly lower hematocrit in RA-treated rats suggests 
the potential for adverse effects systemically due to decreased antioxidant defense or on 
specific extrahepatic tissues, such as bone. 
 We have previously demonstrated that the induction of GNMT by RA is rapid, 
significant after just one treatment, and dose-dependent (18).  The induction of GNMT is 
also consistently characterized by elevations in both activity and protein abundance (11-13).  
Similar to these short-term studies, we have demonstrated that GNMT activity and/or 
abundance in rats treated with RA at all timepoints from two to 24 wk.  The increase in 
GNMT may be due in part to the effects of RA on folate one-carbon metabolism.  Rats fed a 
diet high in retinyl acetate or retinyl palmitate or treated with RA have suppressed MTHFR 
activity and/or elevated MS activity (15,24,27).  Either of these alterations, or both in 
concert, would be expected to lower 5-CH3-THF concentrations, which was measured and 
observed in rats fed high-vitamin A diets (27). GNMT activity can be enhanced by 
phosphorylation of the protein, but when 5-CH3-THF is bound to GNMT, this phosphorylation 
was shown to be inhibited in vitro (5).  Therefore, with lower intracellular levels of 5-CH3-
THF in the liver, the allosteric regulation of 5-CH3-THF would be relieved, GNMT might be 
more easily phosphorylated and specific activity might increase.  Perturbation of folate 
status and homocysteine concentrations have been documented in two studies of humans 
treated with retinoids.  Patients treated with 13-cis-retionic acid (0.5 mg/kg body weight) for 
45 d had elevated plasma homocysteine (28), whereas Chanson et al (29) found no change 
in plasma homocysteine, but folate metabolism was perturbed such that 5-CH3-THF levels 
decreased by ~15-20%. 
In addition to the potential role of altered folate metabolism, transcriptional and/or 
translational control of GNMT is suggested by the strong correlation between GNMT protein 
abundance and activity as was found here (r = 0.511, p < 0.001) and in a previous study 
(13).   Although approximately half the change in GNMT activity can be explained by altered 
transcriptional and/or translational control of GNMT by RA administration, the mechanism by 
which this occurs is not fully understood.  A likely explanation may be found in the recent 
analysis of the promoter region of GNMT which identified several putative RAR and RXR 
binding sites within the 1800 kb upstream of the transcriptional start site (30).  Furthermore, 
a binding site for Sp1 was also identified and Sp1 has been implicated in RA-induced 
expression of other proteins in several extrahepatic tissues (31-33).   Immunoprecipitation 
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for RAR or RXR followed by immunoblotting for RAR and Sp1 has demonstrated that 
RAR/RXR can interact directly with Sp1 to stimulate transcription (31).  However, the 
induction of GNMT by retinoids has been shown to be tissue-specific (13) and these 
interactions between RAR/RXR and their putative binding sites within the GNMT promoter or 
Sp1 have not been described in the liver.  Rather, when HepG2 cells, a rat hepatoma cell 
line, were used to characterize the interactions at the human MRP3 gene promoter, 
RAR/RXR was shown to decrease Sp1 binding in a dose-dependent manner (34).  Notably, 
the promoter for this gene does not appear to contain either a RARE or atypical RARE, so 
decreased Sp1 binding may not be the effect observed within a promoter with a RARE site 
in liver.  Additional characterization of the GNMT promoter and its interactions with 
transcription factors presents a promising direction for future investigations into the 
regulation of GNMT.  
 Despite the long-term upregulation of GNMT, the level of global and CpG island DNA 
methylation and plasma homocysteine levels were maintained.  We hypothesize this might 
be due to the intermittent nature of the treatment regimen or that other transmethylation 
reactions might be compromised in favor of maintenance of DNA methylation patterns.  
Retinoic acid has unique characteristics of absorption, transport, and metabolism relative to 
other forms of vitamin A, such as retinol or carotenoids (35,36).  Retinoic acid is rapidly 
absorbed and travels to the liver via the portal vein and bound by albumin, rather than by 
absorption and transport in chylomicrons and entrance to circulation after lymphatic 
circulation, as for other forms of vitamin A.  Additionally, the half-life of all-trans-retinoic acid 
in plasma is <1 hr in both rodents and humans, and it is not stored in neither liver nor 
extrahepatic tissues (35,37).  Given the observed kinetics of retinoic acid, it is possible that 
daily RA treatment is necessary for alteration of DNA methylation status and also suggests 
the possible influence of other regulatory mechanisms in addition to the upregulation of 
GNMT.  It is also possible that there were specific changes in DNA methylation patterns that 
were not measurable by this assay, which only assesses total changes in methylation 
status.  Interestingly, since our initial report of RA-induced hypomethylation, studies have 
been performed in vitro with the aim of identifying agents for reprogramming of cells for 
cloning.  Eilertsen et al (38) report that in bovine somatic cells, treatment with RA (100 
nmol/L) induced GNMT activity, resulting in a 25% decrease in 5-methylcytosine content of 
DNA and upregulation of Oct4, a biomarker of pluripotency.  Although this study was 
preliminary in nature, it is interesting to note the dramatic effects on cellular phenotype 
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associated with RA-induced upregulation of GNMT expression and DNA hypomethylation.  
Genomic and CpG island DNA hypomethylation have also been observed in the tissue of 
cleft palates induced by maternal RA treatment of mice during pregnancy (39). 
Unfortunately, there appears to be little to no data characterizing the effect of RA on DNA 
methylation or the complete complement of methyl group and homocysteine pathways in 
humans.  Given the evidence of altered folate and homocysteine metabolism in humans 
(28,29), this may be a worthy avenue of investigation.   
In this study, there were few signs of hepatotoxicity as evidenced by a lack of effect 
on plasma ALT and AST activities, and very moderate trends towards decreased body 
weight, weight gain, and increased relative liver weight.  Retinoid treatment in 
dermatological patients may be accompanied by transient increases in ALT or AST that are 
normally reversed by ending treatment (40).  In this experiment, ALT and AST activity was 
only measured at 16 and 24 wk (16 wk data not shown) and although there were no 
significant differences between groups at either time, it’s possible that a transient increase 
was missed.  Our results are also consistent with the results of Hotchkiss et al (41), who 
also found no change in plasma ALT and AST activity in rats given 10 or 15 mg RA/kg body 
weight – a larger dose than that used here, more similar to that prescribed to leukemia 
patients - for 10 or 15 wk.  These results indicate minimal risk of hepatotoxicity; however 
chronic RA-treatment was not without negative effects.  
Hematocrit was significantly decreased in response to both low and high RA 
treatment.  While the control animals’ hematocrit levels increased, as would be expected for 
a growing rat (42), hematocrit levels did not increase at a similar pace in RA-treated 
animals, suggesting compromised hematopoiesis.  Although vitamin A treatment is often 
used for the prevention and treatment of anemia (36), there are also clinical, experimental, 
and epidemiological data that retinoic acid can negatively affect bone and/or blood cell 
formation.  In a case study of an infant suffering from vitamin A intoxication, the bone 
marrow aspirant was found to contain vacuolated or binucleated erythroblasts (43).  A follow 
up in vitro study of primary bone marrow mesenchymal stem cells and K-562 cells 
(multipotent, hematopoietic) found that exposure to 20-80 µmol/L RA resulted in the 
inhibition of cell proliferation (43).  Alternatively, bone marrow diameter and area were 
decreased in both male and female rats given 15 mg RA/kg body weight for a treatment 
period of 15 weeks (41).  However, given the larger dosage used in this study and the lack 
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of effect in rats given a lower dose of RA or 13-cis-retinoic acid, it seems unlikely that 
reduced marrow content could account for the differences in hematocrit observed in our 
investigations.  The epidemiological data tells a slightly different story.  The results of four 
large epidemiological studies regarding the effect of vitamin A on bone suggests that intake 
as low as twice the RDA could be associated with increased risk of osteoporosis and risk of 
fracture (36).  Although others have not always shown a similar effect, there are several 
other potential side effects that warrant consideration in a risk-benefit analysis of treatment 
with retinoids.  In addition to the commonly reported side effects such as skin and eye 
irritation, retinoids are well known to be teratogenic (10).   Although still controversial, 
emerging data also suggests that retinoid treatment may be linked to the development or 
exacerbation of irritable bowel syndrome (42) and depression and suicidal tendencies (45).  
Lastly, we have shown a detrimental effect on antioxidant defense as indicated by lower 
plasma glutathione concentrations at 24 wk.  Hepatic levels may be more sensitive to 
retinoid treatment as de Oliviera et al (46) reported decreased hepatic glutathione 
concentrations after only 7 d of treatment, thereby creating an pro-oxidant environment. 
Intermittent treatment has been studied as an attractive option for therapeutic use 
due to associated negative side effects. When intermittent oral treatment with isotretinoin 
was provided for 6 mo, it was equally efficacious in reducing moderate acne as daily 
treatment, but it was not as successful in ameliorating severe acne (47).  Although daily oral 
isotretinoin treatment remains the gold standard of systemic acne treatment (48), the side 
effects associated with the intermittent treatment were less frequent and less severe than 
those associated with daily treatment (47).  The data from our study suggests that while 
overt clinical signs of vitamin A toxicity may not be present, metabolic perturbations and 
lowered hematocrit develop after just a few weeks and persist even with non-daily dosing of 
RA.  Antioxidant defense is also compromised after long-term supplementation.  Although 
symptoms of retinoid toxicity generally subside with no ill effects after withdrawal of RA 
treatment (19), there remains the possibility that perturbations experienced during treatment 
could put the patient at greater risk for complications in the future.  
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CHAPTER 4: Type I diabetes leads to tissue-specific DNA hypomethylation in male 
rats 
Published in the Journal of Nutrition, 2008;138:2064-9 
Kelly T. Williams, Timothy A. Garrow, and Kevin L. Schalinske 
 
Abstract 
Numerous perturbations of methyl group and homocysteine metabolism have been 
documented as an outcome of diabetes.  It has also been observed that there is a transition 
from hypo- to hyperhomocysteinemia in diabetes, often concurrent with development of 
nephropathy.  The objective of this study was to characterize the temporal changes in 
methyl group and homocysteine metabolism in the liver and kidney, as well as to determine 
the impact these alterations have on DNA methylation in type 1 diabetic rats.  Male 
Sprague-Dawley rats were injected with streptozotocin (60 mg/kg body wt) to induce 
diabetes and samples were collected at 2, 4 and 8 wk.  At 8 wk, hepatic and renal betaine-
homocysteine S-methyltransferase activities were greater in diabetic rats, whereas 
methionine synthase activity was lower in diabetic rat liver and there was no difference in 
kidney.  Cystathionine β-synthase abundance was greater in the liver, but less in the kidney 
of diabetic rats.  Both hepatic and renal glycine N-methyltransferase (GNMT) activity and 
abundance were greater in diabetic rats; however, changes in renal activity and/or 
abundance were present only at 2 and 4 wk, whereas hepatic GNMT was induced at all 
timepoints.  Most importantly, we have shown for the first time that genomic DNA was 
hypomethylated in the liver, but not the kidney in diabetic rats.  These results suggest that 
diabetes-induced perturbations of methyl group and homocysteine metabolism lead to 
functional methyl deficiency, resulting in the hypomethylation of DNA in a tissue-specific 
fashion. 
Key words:  diabetes • DNA methylation • folate • homocysteine • rat 
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Introduction 
Perturbation of methyl group metabolism is associated with numerous pathologies, 
including cancer, cardiovascular disease, neurological problems, and birth defects (1-4).  
Methyl group supply is determined largely by two factors: dietary methyl intake and methyl 
group utilization.  The major dietary methyl donors are methionine, choline, and betaine (5).  
Production of 5-methyltetrahydrofolate (5-CH3-THF) from 5-methylenetetrahydrofolate via 
methylenetetrahydrofolate reductase (MTHFR) serves as an endogenous methyl donor.  
Methyl group metabolism consists of four processes: transmethylation, remethylation by 
folate/B12-dependent or -independent means, and transsulfuration.  Transmethylation 
reactions are essential for many biological processes and involve the transfer of a methyl 
group from S-adenosylmethionine (SAM) to various substrates including nucleic acids, 
lipids, and proteins by methyltransferases.  All SAM-dependent methyltransferase reactions 
ultimately result in the generation of S-adenosylhomocysteine (SAH) and subsequently 
homocysteine, which can be remethylated back to methionine or irreversibly catabolized by 
transsulfuration.  Remethylation of homocysteine to generate methionine occurs via folate-
dependent and/or –independent pathways.  For folate-dependent remethylation, the B12-
dependent enzyme methionine synthase (MS) utilizes a methyl group from 5-CH3-THF.  
Betaine-homocysteine S-methyltransferase (BHMT) catalyzes the folate-independent 
remethylation of homocysteine using betaine, a methyl group donor derived from choline 
oxidation.  Catabolism of homocysteine via the transsulfuration pathway begins with the 
irreversible conversion to cystathionine by cystathionine β-synthase (CBS).   
Because methyl group metabolism is important in health and disease, identifying and 
understanding factors that have a regulatory role is essential.  Recently, diabetes has 
emerged as a condition characterized by disrupted methyl group metabolism. In the acute 
diabetic state, the expression and activity of both hepatic phosphatidylethanolamine N-
methyltransferase (PEMT) and glycine N-methyltransferase (GNMT) were elevated.  
Because PEMT and GNMT represent key SAM-dependent enzymes for phosphatidylcholine 
synthesis and regulation of methyl group metabolism respectively, this suggested that 
transmethylation was increased (6-9).  Inappropriate upregulation of GNMT would be 
expected to lead to wastage of methyl groups due to incorporation of the methyl groups into 
sarcosine.  For both type 1 and type 2 diabetic rat models, MS activity was decreased, 
whereas BHMT activity was markedly increased (7-10).  Elevated expression of CBS as a 
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function of diabetes also suggests enhanced catabolism of homocysteine via the 
transsulfuration pathway (7,9,11,12).  The net effect of these alterations was that hepatic 
levels of both methionine and betaine were decreased (9,11), suggesting the potential 
development of methyl deficiency.   Furthermore, both the activity of MTHFR in lymphocytes 
and the ratio of intracellular SAM:SAH, an indicator of transmethylation potential, in 
erythrocytes were decreased in diabetic nephropathy with an inverse relation to the severity 
of illness (13).  Transmethylation flux has also been shown to be suppressed in diabetics 
with renal dysfunction (14).  Taken together, this suggests that a diabetic condition has a 
profound impact on methyl group metabolism and that both the liver and kidney may be 
important in the pathophysiological progression of the disease.  
To date, most studies have been conducted early in the progression of the disease or 
were cross-sectional.  The goal of this study was to determine whether the perturbations of 
methyl group metabolism associated with a diabetic condition are sustained over time and 
how this might contribute to a functional methyl group deficiency, ultimately resulting in 
genomic hypomethylation and altered expression of proteins associated with DNA 
methylation, such as DNA methyltransferase 1 (DNMT1) (15).  Based on evidence that 
aberrations of methyl group metabolism were more severe in diabetics with renal 
dysfunction (13,14), it was also of interest to determine whether these effects were tissue-
specific. 
 
Materials and Methods 
Chemicals and reagents.   Reagents were obtained as follows:  [14C-methyl]-betaine was 
obtained from Moraveck; Coomassie Plus Protein Reagent, Pierce Chemical; DL-
homocysteine thiolactone, Sigma-Aldrich Chemical; DNMT1 (K-18) antibody and goat anti-
rabbit IgG-horseradish peroxidase, Santa Cruz Technologies; enhanced 
chemiluminescence Western blotting detection reagents and 5-[14C]-methyl-THF, Amersham 
Pharmacia; goat anti-mouse horseradish peroxidase secondary antibody Southern 
Biotechnology; phenylmethylsulfonyl fluoride (PMSF), Calbiochem; and S-adenosyl-L-[3H]-
methionine, New England Nuclear.  The GNMT antibody was provided by Y-M.A. Chen 
(National Yang-Ming University, Taipei, Taiwan) (16).  The CBS antibody was provided by J. 
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Kraus (University of Colorado Health Sciences Center).  All other reagents were of analytical 
grade.  
 
Rats and diets.  All animal experiments were approved by and conducted in accordance 
with guidelines established by Iowa State University Laboratory Animal Resources.  Thirty 
male Sprague-Dawley rats (100-124 g) were housed individually in plastic cages with a 12-h 
light-dark cycle.  All rats were given ad libitum access to a semi-purified diet (17) and water.  
After an acclimation period (4 d), rats were randomly assigned to either the control or 
diabetic treatment group for a total treatment time of 2, 4, or 8 wk (5 rats per group per 
timepoint).  One diabetic rat assigned to wk 8 died during wk 6.  All rats were given a single 
intraperitoneal injection of either vehicle (10 mmol/L citrate buffer, pH 4.5) or streptozotocin 
(STZ, 60 mg/kg body wt), for induction of type 1 diabetes.  At each timepoint, rats were 
anesthetized with an intraperitoneal injection of ketamine and xylazine (90 and 10 mg/kg 
body wt respectively), and heparinized whole blood samples were collected via cardiac 
puncture.  An aliquot of whole blood was saved for analysis of blood glucose (# 510, Sigma-
Aldrich).  The remaining blood was centrifuged at 4,000 × g for 5 minutes, followed by 
removal of the plasma layer and storage at -20°C unti l analysis.  The liver and left kidney 
were rapidly excised and a portion of each tissue was homogenized in ice-cold buffer 
containing 10 mmol/L sodium phosphate (pH 7.0), 0.25 mol/L sucrose, 1 mmol/L EDTA, 1 
mmol/L sodium azide and 0.1 mmol/L PMSF.  After centrifugation at 20,000 × g for 30 min at 
4°C, β-mercaptoethanol was added to the supernatants to a final concentration of 10 
mmol/L.  Remaining tissues were snap frozen in liquid nitrogen and stored at -70°C prior to 
isolation of genomic DNA (cat # A1125, Promega). 
 
GNMT and PEMT  GNMT and PEMT represent two important SAM-dependent 
transmethylation enzymes that also function to regulate homocysteine and methyl group 
metabolism.  GNMT activity was determined based on the method of Cook and Wagner (18) 
with minor modifications (17).  GNMT abundance was assessed using immunoblotting and 
subsequent chemiluminescent detection.  The 32 kDa subunit was separated using SDS-
PAGE.  The protein was transferred to a nitrocellulose membrane and incubated with GNMT 
antibody followed by incubation with goat anti-mouse horseradish peroxidase secondary 
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antibody.  Densitometric analysis (SigmaGel Software, SPSS, Chicago, IL) was used for 
relative quantification of GNMT abundance.  For PEMT activity, frozen liver was 
homogenized in 10 mmol/L Tris-HCl (pH 7.4) and 0.25 mol/L sucrose.  Following 
centrifugation at 16,000 × g  for 20 min at 4°C, the supernatant was removed and 
centrifuged at 100,000 × g for 60 min at 4°C.  The resulting microsomal pellet w as 
resuspended in 0.25 mol/L sucrose.  The enzymatic activity of PEMT was determined using 
the method of Duce et al (19) with minor modifications (6).     
 
BHMT and MS  Remethylation of homocysteine to methionine by the folate/B12-
independent and dependent pathways is controlled by the enzymes BHMT and MS, 
respectively.  For both enzyme assays, fresh homocysteine solutions (100 mmol/L) were 
prepared daily by dissolving a thiolactone derivative in 2 mol/L sodium hydroxide followed by 
neutralization with saturated monopotatssium phosphate (20).  As described previously (7), 
BHMT and MS activities were assessed by radioisotopic assays utilizing [methyl-14C-] 
betaine (20) and [methyl-14C-] tetrahydrofolate (21), respectively.   
 
CBS   The irreversible catabolism of homocysteine by the transsulfuration pathway is 
initiated by the reaction catalyzed by CBS.  Abundance of CBS was determined using 
immunoblotting and chemiluminescence in a method similar to that described for GNMT 
(22). The 63 kDa subunit of CBS was isolated using SDS-PAGE.  After electrophoretic 
transfer to nitrocellulose, the immunoblot was incubated with a polyclonal CBS antibody 
followed by incubation with goat anti-rabbit horseradish peroxidase secondary antibody and 
subsequent chemiluminescent and densitometric analysis.  
 
Homocysteine, SAM, and SAH analysis  Derivatization of plasma samples was performed 
for determination of plasma homocysteine as described by Ubbink et al (23) with minor 
modifications (7).  Homocysteine was analyzed by HPLC with fluorometric detection by 
injecting 100 µL of sample onto a µBondapak C18 Radial-Pak column (Waters, Milford, MA) 
using a mobile phase of 40 mL/L acetonitrile in 0.1 mol/L potassium phosphate buffer (pH 
2.1).  The addition of N-acetylcysteine (1 mmol/L) to each sample prior to derivatization 
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served as an internal standard.  For analysis of hepatic SAM and SAH concentrations, liver 
samples were prepared using the method of Fell et al (24) and SAM and SAH were 
separated and quantified by reverse-phase HPLC with UV detection as described (7).   
 
DNA methylation status  Digestion of hepatic and renal DNA followed by cytosine 
extension was performed as described (25)
 
 for assessment of DNA methylation status.  
DNA (1.0 µg) was digested using the methylation-sensitive restriction enzymes HpaII and 
BssHII (New England Biolabs) for determination of global and CpG island methylation, 
respectively.  For the cytosine extension assay, a reaction mixture of the DNA digest, 10X 
PCR Buffer II (without MgCl2), 25 mmol/L MgCl2, 0.5 U Amplitaq DNA Polymerase (Applied 
Biosystems), and [3H]-dCTP was incubated at 55˚C for 1 h.  Following incubation, samples 
were applied to Whatman DE-81 ion exchange filter paper and washed in 0.5 mol/L sodium 
phosphate buffer (pH 7.0) three times, dried, and 3H incorporation was assessed using liquid 
scintillation counting. 
 
DNMT1 abundance  The Western blotting procedure described for GNMT and CBS was 
also used to determine the DNMT1 abundance, with the following modifications.  For 
DNMT1, the primary and secondary antibodies used were goat polyclonal anti-DNMT and 
donkey anti-goat, respectively.   
 
Statistical analysis  For each timepoint, the mean values of each treatment group were 
subjected to a Student’s t test (SigmaStat, SPSS, Chicago, IL).  A Mann-Whitney rank sum 
test was used when variances were unequal.  Correlations were determined using the 
Pearson product moment correlation method.  Differences were considered significant at P 
< 0.05. 
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Results 
Methyl group metabolism is perturbed by diabetes 
Blood glucose levels were greater in diabetic rats than control rats at all timepoints 
(72, 151, and 185% greater than control at wk 2, 4, and 8, respectively, Table 1).  Plasma 
homocysteine levels were lower in the diabetic group at all timepoints. (76, 65, and 53% of 
control at wk 2, 4, and 8, respectively, Table 1). 
 
Table 1.  Circulating concentrations of glucose and homocysteine in control and diabetic rats.1 
        
Time,wk 
    
    
2   4   8 
Blood glucose mmol/L 
Control 12.2 ± 0.3 9.7 ± 0.5 9.8 ± 0.7 
Diabetic 21.0 ± 1.7* 24.4 ± 2.8* 27.9 ± 1.1* 
Plasma 
homocysteine µmol/L 
Control 9.1 ± 0.3 10.0 ± 2.0 7.4 ± 0.8 
Diabetic 2.2 ± 0.2* 3.5 ± 0.5* 3.5 ± 0.6* 
              
1 Values are mean ± SEM (n= 4-5).  *Different from control at a given timepoint,  
P < 0.05.   
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Consistent with earlier short-term studies (7,8,10), remethylation, by both folate-
dependent and –independent pathways, was also altered by a chronic diabetic state.  At 8 
wk, hepatic BHMT activity was elevated (95%) and hepatic activity of MS was markedly 
lower (81%) in diabetic rats compared to controls (Table 2).  In the kidney, BHMT activity 
was greater in diabetic rats than controls, but there was no significant change in MS activity.  
It should be noted that renal BHMT activity level in both control and diabetic rats was very 
low and thus the metabolic consequences of this increase may be minimal.   
There was a sustained increase in hepatic CBS abundance in the diabetic rat, with 
an increase of 35% at 8 wk (Fig. 1).  In contrast, renal CBS abundance was decreased 33% 
at 8 wk in the diabetic group compared to controls, which would also be expected to 
 
 
Table 2.  Hepatic and renal remethylation enzyme activity levels in control and diabetic rats at 
8 wk after induction of diabetes.1 
     
Control    Diabetic    P-value  
     BHMT Activity  nmol Met/(h • mg protein)  
  Hepatic  
 
73 ± 10 
 
142 ± 16 
 
0.006 
Renal  
 
0.3 ± 0.1 
 
1.1 ± 0.1 
 
<0.001  
MS Activity  pmol/(min • mg protein)  
  Hepatic  
 
24.0 ± 2.9 
 
4.5 ± 1.6 
 
<0.001  
Renal  
 
209 ± 28  
 
148 ± 24  
 
0.149 
              
1 Values are mean ± SEM, (n = 4-5).   
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contribute to a sparing of methyl groups in the kidney by reducing the catabolism of 
homocysteine.  For both tissues, similar changes were also found in diabetic rats at 2 and 4 
wk (data not shown), consistent with previous short term studies (7,11,12).  
The activity and/or abundance of the SAM-dependent methyltransferases (i.e. 
PEMT, GNMT) assessed were elevated as a result of a diabetic condition.    Hepatic PEMT 
activity was elevated 31% at 8 wk (diabetic vs. control, 232 ± 9 vs. 177 ± 13 pmol/(min • mg 
protein), P = 0.012), which is similar to results from an acute (1 wk) study in diabetic rats (6). 
The activity and abundance of hepatic GNMT were greater in the liver of the diabetic 
rat compared with control values at all timepoints (Fig. 2A), although the magnitude was 
diminished with time.  The temporal pattern of GNMT induction by diabetes was tissue- 
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Figure 1.  Hepatic and renal cystathionine β-synthase (CBS) abundance in control and 
diabetic rats at 8 wk after induction of diabetes.  Values are mean ± SEM, (n= 4-5).  
*Different from control, P < 0.05.  A representative blot is shown.   
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specific.  Renal GNMT activity was elevated at 2 and 4 wk in diabetic rats, but was not 
different from control values at 8 wk (Fig. 2B).  Likewise, renal GNMT abundance was only 
greater at the 2 wk timepoint in diabetic rats. 
 
DNA methylation status is affected by a diabetic condition in the liver, but not the 
kidney 
DNMT1 protein abundance and SAM and SAH concentrations in the liver, as well as 
hepatic and renal global and CpG island methylation status were assessed as indicators of 
methyl group balance.  There was no difference in hepatic SAH concentrations, but both 
hepatic SAM levels and the SAM:SAH ratios were slightly lower in diabetic rat liver 
compared to the control; however, this was not statistically significant (Table 3).   However, 
hepatic DNMT1 abundance was 45% greater in diabetic rats than in controls at 8 wk (Table 
3).   
DNA methylation status was assessed using the cytosine extension DNA methylation 
assay (25), wherein endogenous DNA hypomethylation is indicated by an increase in [3H]-
dCTP incorporation.  For liver, there was no significant difference in genomic DNA 
methylation between control and diabetic rats at 2 wk.  However, there was a trend toward 
greater [3H]-dCTP incorporation in diabetic rats at 4 wk (P = 0.074), and a significant 
increase  of 70% in diabetic rats compared to controls at 8 wk (Fig. 3, P = 0.004).  Hepatic 
CpG island DNA was hypomethylated in diabetic rats at 2 wk; however, there were no 
differences in CpG island methylation status at 4 or 8 wk (Appendix A).  Interestingly, there 
was a strong positive correlation between the induction of hepatic GNMT activity and the 
degree of CpG methylation in the liver for all timepoints combined (n = 29, r = 0.74, P < 
0.01).  In marked contrast to hepatic tissue, there were no differences in renal DNA 
methylation status at any timepoint.  Taken together, this data suggests that perturbations of 
hepatic methyl group metabolism by a diabetic condition were sustained through 8 wk, with 
subsequent alterations of DNA methylation status and elevated DNMT1 abundance, 
whereas the kidney appears to be less sensitive. 
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Figure 2.  Hepatic GNMT activity and abundance in the liver (A) and kidney (B) of control 
and diabetic rats at 2, 4, and 8 wk after induction of diabetes.  Values are mean ± SEM (n= 
4-5).  *Different from control at a given timepoint, P < 0.05. 
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Table 3.  SAM and SAH concentrations and DNMT1 abundance in the liver of type 1 
diabetic male rats at 8 wk. 
      
Control 
 
Diabetic 
  
  SAM 28.0 ± 4.5 22.3 ± 5.8 
nmol/g liver 
 SAH 4.8 ± 0.5 5.5 ± 0.8 
nmol/g liver 
 SAM:SAH 6.4 ± 1.4 4.6 ± 1.4 
 
 DNMT1 abundance 1.00 ± 0.16 1.46 ± 0.05* 
Fold of control 
1
 Values are mean ± SEM, (n = 4-5).  *Different from control, P < 0.05.   
 
Discussion  
Diabetes and its progression have been shown to be associated with secondary 
pathologies, including both micro- and macrovascular complications (26).  Based on our 
previous acute diabetes studies that indicated aberrant methyl group metabolism in the liver 
(6-8), we postulated here that a chronic diabetic condition would ultimately result in more 
overt methyl group deficiency.  Ultimately, this would be expected to compromise important 
SAM-dependent transmethylation reactions, such as the methylation of DNA.  Indeed, global 
DNA hypomethylation was observed in the rat liver 8 wk after the induction of diabetes.  To 
our knowledge, this is the first report demonstrating an association between diabetes and 
genome-wide epigenetic alterations of DNA.  This finding may have significant implications 
for mechanistically linking diabetes to complications that are known to be influenced by DNA 
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Figure 3.  Genomic DNA methylation in the liver of control and diabetic rats at 2, 4, and 8 
wk after induction of diabetes.  Greater incorporation of [3H]-dCTP indicates a greater 
degree of endogenous hypomethylation.  Values are mean ± SEM (n= 4-5).  *Different from 
control at a given timepoint, P < 0.05.  
 
methylation and aberrant gene expression, such as cardiovascular disease and cancer (27-
29). 
In this study, plasma homocysteine concentrations in diabetic rats were lower than 
those in the controls throughout the treatment period.  This finding is consistent with an 
earlier report which has shown that 10 wk after induction of diabetes, plasma homocysteine 
levels remained lower in diabetic rats than controls despite the onset of early renal 
dysfunction as evidenced by elevated urinary protein (30).  Here, using plasma creatinine as 
an estimate of the glomerular filtration rate (GFR), diabetic hyperfiltration was present as 
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evidenced by lower plasma creatinine levels (Appendix A).  Typically, plasma 
homocysteine levels are inversely related to the GFR; thus, during the hyperfiltration that 
occurs in early diabetes in both humans and animal models, hypohomocysteinemia is 
observed (31-33).  However, there was not a significant correlation between plasma 
homocysteine and creatinine concentrations (r = 0.279, P = 0.15), suggesting that greater 
excretion of homocysteine due to hyperfiltration is not the only determinant of circulating 
homocysteine concentrations.  This conclusion was also supported by the multivariate 
analysis of Wollesen et al (33). 
Given the role of the kidney in homocysteine balance (13,14,31), it was of interest to 
determine the effects of a diabetic condition in both the liver and the kidney.  Hepatic 
perturbations of methyl group metabolism were sustained throughout the duration of the 
study, whereas the alterations in renal methyl group metabolism were more transient and no 
change in DNA methylation was observed.  In support of this finding, genomic 
hypomethylation has been observed in the liver, but not the kidney, of rats fed a methyl-
deficient diet (34).  Dietary-induced methyl deficiency is characterized by: genomic and 
regional hypomethylation; perturbed expression of DNA methyltransferases and methyl-
binding proteins; aberrant histone modifications; uracil misincorporation; and DNA strand 
breaks (15,34-37).  All of these alterations contribute to genomic instability and thus play an 
important role in carcinogenesis.  Induction of DNMT1 is characteristic of dietary-induced 
methyl deficiency (15,37) and was also observed in our diabetic rats at wk 8 in this 
experiment.   
The results presented here suggest that alterations of methyl group metabolism were 
sustained in the liver, whereas the kidney was less sensitive to such changes.  Despite 
differences in the pathology of type 1 vs. type 2 diabetes, the characteristic changes in 
methyl group metabolism appear to be similar for both conditions.  The increases in hepatic 
GNMT, PEMT, BHMT, and CBS activity and/or abundance, as well as the decrease in 
hepatic MS activity has been previously described in acute models of type 1 and/or 2 
diabetes (6-12).  The data presented here suggests that these hepatic effects are sustained 
for at least 8 wk.  However, in the kidney there was only transient induction of GNMT, a 
decrease in CBS abundance, and no difference in either MS activity or DNA methylation 
status.  Taken together, the diabetic rat model shows similarities to methyl-deficient rat 
model, such that hepatic methyl group and methionine metabolism is perturbed for at least 8 
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wk, resulting in genomic hypomethylation and aberrant expression of DNMT1.  Moreover, 
these effects are clearly tissue-specific. 
The changes induced by a diabetic condition could have secondary consequences, 
particularly based on the collective changes in GNMT and DNA methylation.  GNMT is 
multifunctional and in diabetes it may be upregulated to generate pyruvate from methionine 
for gluconeogenesis, especially as its expression is limited to gluconeogenic tissues (38); it 
is also a proposed regulator of the SAM:SAH ratio (39).  Thus, upregulation of GNMT in 
diabetes would be expected to decrease the SAM:SAH ratio, thus limiting the intracellular 
transmethylation potential and numerous transmethylation reactions, including DNA 
methylation.  Although the hepatic SAM:SAH in diabetic rats in this study was not 
significantly different, DNA hypomethylation was clearly evident.  For liver, dietary methyl 
deficiency is an independent carcinogen and has long been known to cause 
hypomethylation in the promoter regions of oncogenes (40,41).  With the functional methyl 
deficiency associated with a diabetic condition, it would be expected that diabetes may also 
be associated with increased risk of hepatocellular carcinoma.  This is supported by several 
epidemiological studies examining the relationship between diabetes and cancer have found 
an increased  incidence of liver cancers of both type 1 and/or type 2 diabetic patients (42-
45).  In addition to hepatic carcinogenesis, hypomethylation of DNA and alterations of 
methyl group metabolism have also been implicated in the development of vascular 
diseases.  Global DNA hypomethylation has been observed in advanced atherosclerosis in 
the rabbit and mouse, as well as in humans (27,28).  Aberrant DNA methylation patterns 
have been detected early in the development of the disease (46) and become more 
prevalent with the progression of atherosclerosis, thus suggesting that epigenetic 
mechanisms may play a critical role in the atherosclerotic pathogenesis.  It remains to be 
determined if diabetes-induced changes in DNA methylation are linked to cardiovascular 
disease.  
Regulation of specific enzymes of methyl group metabolism may also impact DNA 
methylation status and pathogenesis of disease.  Deficiency of MS or MTHFR were both 
reported to have negative effects on cerebral vascular function and lipid deposition was 
found in the aorta of mice hetero- or homozygous for the MTHFR knockout (47,48).  Both 
MTHFR mutants also had lower SAM:SAH ratios and regions of both DNA hypomethylation 
in several tissues, suggesting impaired methylation capacity (48).  GNMT is proposed to be 
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the primary regulator of methyl group supply and utilization and thus, aberrant regulation of 
GNMT activity might be expected to perturb DNA methylation status.  A recent report by 
Martinez-Chantar et al (49) demonstrates that in GNMT-knockout mice methylation status of 
specific genes was increased.  We found a similar relationship in the diabetic rat liver, such 
that lower levels of GNMT activity were correlated with a greater degree of CpG island 
methylation and upregulation of GNMT was associated with hypomethylation.  It would 
appear that decreasing GNMT activity was associated with the silencing of genes, whereas 
increasing GNMT activity would favor the activation of genes.  
DNA methylation has also been closely linked to patterns of histone methylation and 
other histone modifications which could also contribute to aberrant gene expression and 
development of disease (29).  Recently it was reported that in lymphocytes cultured under 
high glucose, methylation patterns of histones were altered in the regions of several genes 
which may be associated with diabetes via signal transduction, transporter, inflammation, 
and oxidant stress pathways (50).  Mechanistically, evidence suggests that aberrant 
expression of methyl-binding proteins, histone methyltransferases and histone acetylases 
are also involved (15,37,50). 
In summary, we have shown for the first time that chronic alterations of methyl group 
metabolism concomitant with genomic hypomethylation in the rat liver as a result of type 1 
diabetes.  In contrast, the kidney was more resistant to perturbations of methyl group 
metabolism and no changes were found in renal DNA methylation.  The identification of 
widespread genomic DNA hypomethylation is a particularly novel finding and supports our 
hypothesis that a functional methyl deficiency develops in a diabetic state and may have 
implications concerning gene expression, DNA stability, and the development of secondary 
complications, such as vascular diseases and tissue-specific carcinogenesis.  Because 
regulation of GNMT appears to be a major determinant of DNA hypomethylation, it is of 
interest to note that the tissues shown to be susceptible to cancer development in diabetes 
(42-45) are the same tissues that are known to express GNMT (38).  Future research efforts 
will be geared towards further characterizing these metabolic and epigenetic alterations to 
gain a better understanding of the consequences of these changes and identifying timely 
dietary interventions that might be successful in ameliorating negative effects. 
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CHAPTER 5:  Tissue-specific alterations of methyl group metabolism and DNA 
hypermethylation in the Zucker (type 2) diabetic fatty (ZDF) rat 
A manuscript to be submitted to the American Journal of Physiology – Endocrinology and 
Metabolism 
Kelly T. Williams and Kevin L. Schalinske 
 
Abstract 
Altered methyl group and homocysteine metabolism was tissue-specific, non-
transient, and preceded hepatic DNA hypomethylation in streptozotocin (STZ)-induced type 
1 diabetic rats.   Similar perturbations of hepatic methyl group and homocysteine 
metabolism have been shown in the Zucker (type 2) diabetic fatty (ZDF) rat in the pre- and 
early diabetic stages, but the tissue specificity and effect on epigenetic regulation are 
unknown, particularly with respect to disease progression.  With this objective in mind, ZDF 
and lean rats (ZDF/Gmi fa/fa and +/?) were euthanized at 12 and 21 wk of age, representing 
early and advanced diabetic conditions.  At 12 wk, hepatic glycine N-methyltransferase 
(GNMT), methionine synthase, and cystathionine β-synthase (CBS) activity and/or 
abundance were increased, whereas plasma homocysteine was decreased in ZDF rats.  At 
21 wk, GNMT activity was increased in liver and kidney.  In liver only, there was a trend 
toward increased CBS protein abundance (78%) and betaine-homocysteine S-
methyltransferase mRNA expression (~100%).  Phosphatidylethanolamine N-
methyltransferase activity tended to be lower in ZDF liver despite a significant increase in 
mRNA abundance.  Homocysteine levels were decreased in plasma and kidney, but not in 
liver, at 12 and 21 wk.  In contrast to the hypomethylation observed in the STZ-diabetic rat 
liver, hepatic genomic DNA was hypermethylated at 12 and 21 wk in ZDF rats, concurrent 
with a trend toward increased DNMT1 mRNA expression (p = 0.08) at 21 wk.  In conclusion, 
the progression of type 2 diabetes in the ZDF rat was associated with tissue- and disease 
stage-specific aberrations of methyl group and homocysteine metabolism, with persistent 
hepatic global DNA hypermethylation. 
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Introduction  
It is estimated that over 12% of the U.S. population is afflicted with diabetes, with 
type 2 diabetes representing 95% of cases (1).  Diabetes has been identified as a condition 
that can profoundly alter methyl group and homocysteine metabolism (2,3).  There are three 
primary pathways involved in homocysteine metabolism: transmethylation, remethylation via 
folate/B12-dependent or –independent means, and transsulfuration (Figure 1). For 
transmethylation reactions, methionine is activated to S-adenosylmethionine (SAM), which 
serves as the universal methyl group donor for numerous methyltransferases, resulting in 
the methylation of substrates such as nucleic acids, lipids, and proteins.  Methyltransferase 
reactions result in the generation of homocysteine, which can be remethylated back to 
methionine using methyl groups donated by either 5-methyltetrahydrofolate (5-CH3-THF) or 
betaine.  For folate-dependent remethylation, the B12-dependent enzyme methionine 
synthase (MS) utilizes a methyl group from 5-CH3-THF.  Betaine-homocysteine S-
methyltransferase (BHMT) catalyzes the folate-independent remethylation of homocysteine 
using betaine, a methyl group donor derived from choline oxidation.  Alternatively, 
homocysteine can be catabolized through the transsulfuration pathway to cysteine, 
beginning with the irreversible conversion to cystathionine by cystathionine β-synthase 
(CBS).    
We, and others, have previously shown that an early diabetic condition alters methyl 
group and homocysteine metabolism.  Diabetes induced hepatic protein abundance and 
activity of glycine N-methyltransferase (GNMT) and phosphatidylethanolamine N-
methyltransferase (PEMT, 4-9).  Both enzymes have important roles in regulation of methyl 
groups and homocysteine: GNMT is proposed to be a regulator of the transmethylation 
potential via maintenance of the SAM:S-adenosylhomocysteine (SAH) ratio,  PEMT is 
purported to be the greatest consumer of SAM-derived methyl groups (10) and catalyzes the 
sequential trimethylation of phosphatidylethanolamine to phosphatidylcholine.  Induction of 
BHMT and CBS are also consistently observed in diabetic or glucocorticoid-treated 
conditions (4,5,7-9,11,12), whereas the effect of diabetes on MS is not consistent.  In sum, 
these metabolic alterations result in hypohomocysteinemia in the early diabetic condition, 
likely owing in part to greater upregulation of transsulfuration and remethylation via BHMT 
such that it overwhelms increases in transmethylation.  Importantly, similar aberrations are  
  
observed in both type 1 and type 2 diabetic rat models (4,5,7
2 diabetic patients (13,14) 
Progression of diabetes is associated with the development of secondary 
complications, including cardiovascular disease, nephropathy, n
With the development of renal dysfunction in diabetic patients there is a shift from hypo
hyperhomocysteinemia and suppression of MTHFR activity that increases with severity of 
nephropathy (14,15).  Type 2 diabetics with n
the transsulfuration pathway, which likely contributes to decreased homocysteine clearance 
(16).  When studying the progression of diabetes in the streptozotocin
-9), as well as type 1 and type 
europathy, and retinopathy.   
ephropathy also have decreased flux through 
 (STZ)
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diabetic rat, we noted that the effect of diabetes was tissue-specific and sustained 
alterations of hepatic methyl group and homocysteine metabolism appeared to lead to a 
methyl deficient condition, as evidenced by genomic DNA hypomethylation in the liver (7).   
 The progression of type 2 diabetes from prediabetes to the early diabetic state in the 
Zucker (type 2) diabetic fatty (ZDF) rat has been shown nicely by Wijekoon et al. (9), 
however the advanced diabetic condition has yet to be fully characterized.  Poirier et al (14) 
reported no differences between the type 1 and type 2 patients within their study, and the 
SAM:SAH ratio decreased with increasing severity of disease.  Therefore, we hypothesized 
that ZDF rats with advanced diabetes would have perturbed methyl group and 
homocysteine metabolism, including chronic upregulation of GNMT, and develop a methyl-
deficient condition.  Furthermore, due to the functional methyl deficiency, the animals would 
have abnormal DNA methylation and expression of epigenetic regulatory proteins, similar to 
that observed in the STZ-diabetic rat (7) or rats fed methyl-deficient diets (16).  
    
Materials and Methods 
Chemicals and reagents  Reagents were obtained as follows:  3T3 fully methylated DNA, 
BssHII, HpaII, and MspI restriction enzymes, New England Biolabs, Inc. (Ipswich, MA); 5-
[3H]-dCTP, MP Biomedicals (Solon, OH); enhanced chemiluminescence Western blotting 
detection reagents and 5-[14C]-methyl-THF, Amersham/GE Healthcare (Piscataway, NJ); 
CBS antibody (H-300, sc-67154), goat anti-rabbit and goat anti-chicken horseradish 
peroxidase secondary antibodies, Santa Cruz Biotechnology, Inc (Santa Cruz, CA); and S-
adenosyl-L-[3H]-methionine, Perkin Elmer Life Sciences (Waltham, MA).  All other reagents 
were of analytical grade. 
Animals  All animal protocols were approved by and conducted in accordance with the 
guidelines set forth by the Iowa State University Institutional Animal Care and Use 
Committee.  The first set of experiments utilized rats which were purchased at 11 wk of age, 
allowed to acclimate for 1 wk, and terminated at 12 wk of age.  For the second study, rats 
were purchased at 10 wk of age and sacrificed at 21 wk of age.  Each study utilized six lean 
(ZDF/Gmi +/?) and six ZDF (ZDF/Gmi fa/fa) rats (Charles River Laboratories, Wilmington, 
MA) kept in individual cages with a 12:12 hr light:dark cycle and given ad libitum access to 
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water and Purina 5008 diet.  Animals were fasted for 12 hr prior to euthanasia.  Rats were 
anesthetized by intraperitoneal injection with ketamine and xylazine (90 and 10 mg/kg 
respectively).  Blood samples were then collected by cardiac puncture and tissues were 
collected including the liver, right kidney, and heart.  Blood glucose levels were immediately 
assessed using a glucometer.  Plasma and serum samples were collected by standard 
centrifugation methods and stored at -20°C.  Serum insu lin levels were analyzed by 
Rat/Mouse Insulin ELISA Kit (Linco, Inc., St Charles, MO).   A portion of the liver was 
immediately homogenized and cytosolic extracts prepared as previously described (7); the 
remainder of the liver and all other tissues were snap frozen in liquid nitrogen and 
subsequently stored at -70°C.  Protein concentrations of extracts were determined using the 
Bradford assay with Coomassie Protein Plus Reagent (Thermo Scientific). 
 
Enzyme assays  Activities of GNMT, PEMT, and MS were determined using radioisotopic 
assays as previously described (5,6,7,17,18).  Briefly, GNMT and MS activity in the liver, 
kidney, and heart were determined by incubation of cytosolic extracts with reaction mixes 
containing S-adenosyl-L-[3H]-methionine and 5-[14C]-methyl-THF, respectively.  After halting 
the reaction, the unreacted, radiolabeled substrate was removed via sequestration by 
activated charcoal or anion exchange resin.  Hepatic PEMT activity in microsomal extracts 
was assessed in a similar manner by determining the incorporation of S-adenosyl- L-[3H]-
methionine into the lipid fraction by the enzyme in microsomal extracts.  Liquid scintillation 
counting was used to determine the extent of radiolabel incorporation for all assays. 
 
Western blotting  Relative protein abundance was determined using methods previously 
described (7) with minor modifications.  All proteins were separated using SDS-PAGE.  
Ponceau S staining was used to verify equal loading. For assessment of GNMT, blots were 
incubated with a newly-procured affinity-purified chicken antibody   (Aves Labs, Inc., Tigard, 
OR) directed against the following peptide sequence: KER WNR RKE PAF DK (GNMT 
residues #97-110), 1:40000 in TTBS/1% BSA. CBS primary antibody was prepared 1:400 in 
TTBS/1% BSA; goat anti-chicken or anti-rabbit horseradish peroxidase secondary 
antibodies were prepared at 1:5000 in TTBS.  Relative protein amounts were quantified by 
densitometric analysis with QuantityOne software (Bio-Rad Laboratories, Hercules, CA).  
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DNA methylation  Using the method of Pogribny et al (19) and as described previously (7), 
digestion of DNA followed by cytosine extension was used for assessment of DNA 
methylation status in liver, kidney, and heart tissues.  Global and CpG island DNA 
methylation were determined by digesting 1.0 µg DNA from the liver, kidney, or heart using 
the methylation-sensitive restriction enzymes HpaII and BssHII, respectively.  For the 
cytosine extension assay, a reaction mixture of the DNA digest, 10X PCR Buffer II (without 
MgCl2), 25 mmol/L MgCl2, 0.5 U Amplitaq DNA Polymerase (Applied Biosystems), and [3H]-
dCTP was incubated at 55˚C for 1 h.  Following incubation, samples were applied to 
Whatman DE-81 ion exchange filter paper and washed in 0.5 mol/L sodium phosphate 
buffer (pH 7.0) three times, dried, and 3H incorporation was assessed using liquid 
scintillation counting.  Samples were run in duplicate and reactions using either MspI-
digested DNA or mouse 3T3 fully-methylated DNA with the appropriate restriction enzyme 
were used as controls.  When compared to the MspI control, the degree of genomic 
methylation fell within the expected range of 70-90% (20).  
 
Real-time RT-PCR  Upon the first removal from storage, 0.1 g of frozen liver was taken and 
immediately preserved in 1 mL RNALater-ICE (Ambion, Inc, Austin, TX).  This sample was 
subsequently used for RNA isolation using Trizol Reagent (Invitrogen, Carlsbad, CA).  The 
reverse-transcription assay was performed using iScript Select cDNA Synthesis Kit (Bio-Rad 
Laboratories, Hercules, CA).  The resulting cDNA was diluted 50x for use in the PCR 
reaction with iQ SYBR Green Supermix (Bio-Rad Laboratories).  Primers used for RT-PCR 
(Table 1) were designed using PrimerQuest (Integrated DNA Technologies, Inc., Coralville, 
IA).   Samples were run in duplicate, data were normalized to 18S control, and results were 
analyzed using the comparative Ct method.   
 
Statistical analysis  For each timepoint, the mean values of each treatment group were 
subjected to a Student’s t test (SigmaStat, SPSS, Chicago, IL).  A Mann-Whitney rank sum 
test was used when normality or equal variance test failed.  Differences were considered 
significant at P < 0.05, trends were noted when 0.05 < P < 0.1. 
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Table 1. Real-time RT-PCR primers 
Target   Primers (5' → 3') 
GNMT F*: ACA ACA AAG CCC ACA TGG TAA CCC 
  
R: AGC CGA AAC TTA CTG AAG CCA GGA 
PEMT F: TGT GCT CTC CAG CTT CTA TGC ACT 
  R: AGG GAA ATG TGG TCA CTC TGG ACT 
MS F: TTG GCC TAC CGG ATG AAC AAA TGC 
  R: AGC CAC AAA CCT CTT GAC TCC TGT 
BHMT F: ATC TGG GCA GAA GGT CAA TGA AGC 
  R: TGA CTC ACA CCT CCT GCA ACC AAT  
CBS F: AAC ATG TTG TCC TCC CTG CTT GCT 
  R: TCG GCT TGA ACT GCT TGT AGA GGA 
DNMT1 F: TGT GGC AAG AAG AAA GGT GGC AAG  
  R: TGG ATG GAC TTG TGG GTG TTC TCA  
DNMT3a F: AGA GTG TCT GGA ACA CGG CAG AAT  
  R: TGC TGG TCT TTG CCC TGC TTT ATG 
DNMT3b F: TGC GCC TGC AAG ACT TCT TCA CTA  
  R: TGC AGG AAT CGC TGG GTA CAA CTT  
MBD1 F: CCT GCA CCT TTG TGC TGT GAG AAT  
  R: CAG TCT TTG CAC AAT GTC CTG CGT  
MBD2 F: TCA GAA GTA AAC CAC AGC TGG CGA  
  R: ACT AGG CAT CAT CTT GCC GCT TCT  
MBD3 F: GAA GAA GTT TCG CAG CAA GCC ACA  
  R: CAT CTT TCC CGT GCG GAA ATC GAA  
MBD4 F: AGC TAA ACC TCA GGA CAC GAA GCA  
  R: TTG GAC AGGCTG TTG CTA TCT GGA  
MeCP2 F: GCA GCA GCA TCA GAA GGT GTT CAA  
  R: TGC TTG GAA AGG CAT CTT GAC GAG  
18S F: GAA CCA GAG CGA AAG CAT TTG CCA  
    R: ATG GTC GGA ACT ACG ACG GTA TCT  
*F denotes forward primer, R denotes reverse primer. 
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Results 
General characteristics   
The body weights of ZDF rats were significantly greater than their lean counterparts 
at 12 wk, whereas there was no significant difference in total body weight between groups at 
21 wk (Table 2).  For the 21 wk experimental group, it was noted that lean controls gained 
weight for the duration of the study, but the weight gain of ZDF rats plateaued or declined 
beginning around 16 wk of age (Appendix B), despite markedly increased food intake by 
ZDF rats observed at both 12 and 21 wks and throughout the experimental period.  All ZDF 
rats were hyperglycemic, indicating that the animals were indeed diabetic at both 12 and 21 
wk.  There was a trend toward hyperinsulinemia in fasted ZDF rats at 12 wks of age, as 
would be expected in the early stages of type 2 diabetes with insulin resistance.  The 
characteristics of the ZDF rat in the advanced diabetic stage were consistent with those 
reported by others (21). 
 
Perturbed methyl group metabolism in the ZDF rat   
Diabetes produced tissue- and time-specific changes in the expression and activity 
of GNMT and PEMT.  GNMT activity and protein abundance were elevated in the liver of 
ZDF rats compared to lean controls at both 12 and 21 wk of age (Figures 2 and 3).  GNMT 
mRNA abundance also tended towards an increase in the liver at 21 wks (Table 3).  Renal 
GNMT activity was increased only at 21 wk (p = 0.012) without parallel increases in renal 
GNMT protein abundance, suggesting possible post-translational regulation of GNMT 
activity in the kidney.  Unexpectedly, hepatic PEMT activity was unchanged in the diabetic 
rat at 12 wk and there was a trend towards decreased activity at 21 wk (lean vs. ZDF: 88 ± 
10 vs. 62 ± 8 pmol/min х mg protein, p = 0.071).  However, there was a trend towards 
increased hepatic PEMT mRNA abundance at 12 wk and a significant increase of 73% in 
PEMT mRNA abundance in ZDF rat liver at 21 wk (Table 3). 
Removal of homocysteine via folate/B12-dependent and independent remethylation 
or transsulfuration pathways was altered in the ZDF rat.  BHMT mRNA abundance was 
increased in ZDF rat liver at 21 wk.  CBS did not show any changes in mRNA abundance, 
but there was a tissue-specific effect on protein abundance (Figure 3).  Similar to  
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Figure 2.  Increased hepatic and renal activity of GNMT in ZDF rat.  Values are mean ± 
SEM (n= 6).  *Different from control at a given timepoint, P < 0.05. 
 
observations from the STZ-diabetic rat (7), CBS protein abundance was greater in the liver, 
with a trend towards decreased CBP abundance in the kidney when ZDF rats were 
compared to lean controls at 12 wk.  At 21 wk, there were no significant differences in CBS 
protein levels between ZDF and lean rats in neither the early nor advanced diabetic 
conditions.  In the early diabetic condition, there were slight trends towards increased MS 
activity and mRNA abundance in the liver (lean vs. ZDF, 416 ± 40 vs. 498 ± 21 pmol/(min • 
mg protein), p = 0.098, Table 3).  No changes were observed in renal MS activity. With the 
exception of a trend towards increased MS activity in the heart at 21 wk (lean vs. ZDF, 286 ± 
20 vs. 343 ± 22 pmol/(min • mg protein), p = 0.082), there were no significant changes in the 
heart.  In both the early and advanced diabetic conditions, cardiac CBS and GNMT protein     
 Figure 3.  Tissue-specific alterations of GNMT and CBS protein abundance
Representative blots are shown.  Values are mean ± SEM, (n=5
P < 0.05.   
 
abundance were similar and no appreciable GNMT activity was detected.
Regulation of the enzymes of methyl group and homocysteine metabolism and 
concentrations of key intermediates of t
and intracellular concentrations of homocysteine, glutathione, SAM, and SAH were also 
perturbed by a diabetic condition.  There was an identical 37% increase in hepatic SAM 
concentrations and in the SAM:SAH ratio in ZDF rat liver relativ
although it must be noted that the increase in the SAM:SAH ratio did not achieve statistical 
significance (Table 4).  Renal SAM concentrations were elevated in both the acute and 
advanced diabetic conditions
These perturbations likely both contributed to the increased SAM:SAH ratio in the kidney at 
both 12 and 21 wk.   
  Plasma total homocysteine concentrations were decreased 67 and 54% at 12 and 
21 wk respectively (Table 5).  There were no changes in hepatic concentrations of
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he pathways are interrelated.  Accordingly, plasma 
e to controls at 12 wk, 
.  Additionally, SAH levels were lower in ZDF kidney at 12 wks.
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Table 5.  Fasted plasma and tissue concentrations of total homocysteine and glutathione. 
                
Total homocysteine  Total glutathione 
(µmol/L plasma or g tissue) (µmol/L plasma or g tissue) 
                
  
Time 
(wk) Lean ZDF p-value Lean ZDF p-value 
  
   
  
  
Plasma 12 6.8 ± 0.3 2.2 ± 0.1* <0.001 21.0 ± 1.2 19.6 ± 0.7 0.319 
 
21 3.6 ± 0.3 1.6 ± 0.1* <0.001 13.6 ± 0.8 11.3 ± 1.0 0.115 
 
    
Liver 12 155 ± 22 166 ± 10 0.664 5614 ± 261 7582 ± 413* 0.002 
 
21 168 ± 7 203 ± 20 0.240 7088 ± 263 7144 ± 235 0.876 
 
    
Kidney 12 11.0 ± 4.1 4.1 ± 0.7* 0.030 41.8 ± 5.8 102.2 ± 4.1* <0.001 
 
21 6.3 ± 0.9 3.2 ± 1.1 0.059 38.4 ± 10.3 65.4 ± 7.6 0.082 
                
Data are means ± SEM, *indicates significantly different from the control via t-test or rank sum test.  
 
homocysteine, whereas homocysteine concentrations were decreased 63% in the ZDF 
kidney at 12 wk.  Most interestingly, there were significant increases in both hepatic and 
renal total glutathione concentrations at 12 wk.  Renal glutathione levels were also elevated 
in ZDF rats at 21 wk, although this was only observed as a trend. 
 
DNA hypermethylation and upregulation of DNMT1 in the diabetic rat liver 
 In contrast to the development of hepatic global DNA hypomethylation in the 
advanced STZ-diabetic rat (7), marked global DNA hypermethylation was characteristic of 
ZDF rat liver in both early and advanced diabetes (Figure 4).  This effect was specific to 
genomic DNA in the liver; changes were observed in neither global DNA methylation levels 
in kidney and heart nor in CpG island methylation status as measured by the overall 
incorporation of [3H]-dCTP.  Likewise, the mRNA abundance of the DNMTs and MBDs were 
unaltered in early diabetes (Appendix B); however, DNMT1 mRNA abundance was 
increased 95% in the ZDF rat liver at 21 wk (Table 6).  Despite minimal impact on the 
regulation of DNMTs  and MBDs at the mRNA level, dysregulation of global DNA  
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Figure 4.  Hepatic hypermethylation of genomic DNA in ZDF rats at (A) 12 and (B) 21 wk of 
age.  By the method of Pogribny et al (19), incorporation of [3H]-dCTP is inversely related to 
the degree of methylation.  Values are mean ± SEM (n=6 ).  *Different from control, P < 
0.05.  
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Table 6.  Hepatic mRNA abundance of epigenetic regulatory proteins in lean and ZDF rats 
at 21 wk of age. 
    Mean fold induction     
Target   Lean ZDF   p-value 
DNMT1 
 
1.00 ± 0.29 1.95 ± 0.37* 
 
0.042 
DNMT3a 
 
1.00 ± 0.27 0.89 ± 0.12 
 
0.353 
DNMT3b 
 
1.00 ± 0.34 0.92 ± 0.20 
 
0.422 
MBD1 
 
1.00 ± 0.40 1.35 ± 0.29 
 
0.241 
MBD2 
 
1.00 ± 0.17 1.02 ± 0.18 
 
0.467 
MBD3 
 
1.00 ± 0.22 1.03 ± 0.14 
 
0.458 
MBD4 
 
1.00 ± 0.58 0.19 ± 0.03 
 
0.197 
MeCP2   1.00 ± 0.47 0.72 ± 0.15   0.275 
Data are means ± SEM (n=6), * indicates significant difference, P < 0.05 
 
methylation patterns appear to be an early event in the pathogenesis of diabetes in the ZDF 
rat.  
 
Discussion 
Here we demonstrate that during the progression of type 2 diabetes in the ZDF rat, 
there are tissue-specific alterations of methyl group and homocysteine metabolism, with 
concurrent epigenetic dysregulation and abnormal concentrations of key intermediates.  
However, unlike the effects of the chronic type 1 diabetic condition in which genomic DNA 
hypomethylation develops in the liver, hepatic genomic DNA was hypermethylated in the 
ZDF rat, even in the early stages of the disease.   
In early diabetes, both ZDF and type 1-diabetic rat models have been shown to 
exhibit similar perturbations hepatic methyl group and homocysteine metabolism (4-9) and 
which were also observed in the ZDF rats of this study at 12 wk.  The net effect of these 
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metabolic perturbations in the liver in early diabetes seems to favor the loss of methyl 
groups the catabolism of methionine to cysteine via induction of GNMT and the 
transsulfuration pathway.  This might be the anticipated result based the abundance of 
evidence supporting GNMT as a regulator of the SAM:SAH ratio (22) and the known 
induction of CBS expression and activity by glucocorticoids and SAM (23,24).  The 
upregulation of CBS may be a compensatory mechanism for self protection of the liver and 
kidney against the oxidative stress associated with a diabetic condition; CBS activity has 
been shown to be enhanced under conditions of oxidative stress (25).  However, many 
studies have found depletion of glutathione in diabetic tissues (26), so the significance of 
this finding remains unclear.  
It also might seem intuitive that when SAM levels have normalized - as occurred in 
the liver at 21 wk - that regulation would change to maintain transmethylation potential.  As 
such, the induction of GNMT was not as great as it was at 12 wk, with only a 19% increase 
in activity and an 8% increase in protein abundance.  There was also a significant increase 
in BHMT mRNA abundance that was not observed in the early diabetic condition.  In 
diabetes, increases in BHMT mRNA abundance have previously been associated with 
increased BHMT activity (12), thereby we suggest remethylation by BHMT may be 
increased.  Interestingly, PEMT was upregulated at the mRNA level, whereas PEMT activity 
was decreased.  A decrease in production of homocysteine by PEMT and lesser induction of 
GNMT combined with an increase in BHMT activity might be expected to contribute to the 
hypohomocysteinemia that persisted in the advanced diabetic state despite no change of 
CBS protein abundance when ZDF rats were compared to controls.  
The response of the kidney to a diabetic condition appears to be less stringently 
regulated.  Whereas, enzymes of methyl group and homocysteine metabolism appeared to 
be regulated at a transcriptional and/or translational level with respect to SAM 
concentrations in the liver, there was a lesser impact on the enzymes of the kidney and 
furthermore, renal intracellular concentrations of SAM, SAH, homocysteine, and glutathione 
appeared to reflect those in the liver and the plasma.  Renal SAM concentrations were 
elevated at both 12 and 21 weeks in the liver but GNMT activity only increased in the 
advanced diabetic condition and there were not concurrent increases in GNMT protein 
abundance.  We have demonstrated the tissue specificity of GNMT regulation previously in 
response to retinoids (26) as well as the diabetic condition (7).  Beyond the increase in 
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GNMT activity, there were no observed alternations of enzymes, nor was DNA methylation 
status affected in the kidney.  House et al (28) also found a lack of effect of either glucagon 
treatment or STZ-diabetes, whereas Jacobs et al (8) reported that renal MS and MTHFR 
activities were suppressed by a type 1 diabetic condition.  
The liver is unique in that it contains the full complement of pathways.  The kidney 
also contains all pathways, although BHMT is expressed at low levels in the rat kidney (30) 
and MS activity was found not to be quantitatively significant (28,31), making 
transsulfuration the primary route for removal of homocysteine in the kidney.  Homocysteine 
levels in the ZDF liver were not different from controls at 12 or 21 wks, despite decreased 
homocysteine concentrations in both the plasma and kidney.  The low levels of 
homocysteine in the kidney are unlikely to be due to increased urinary excretion because 
this was not shown to be a significant method of homocysteine removal in healthy or STZ-
diabetic kidneys (8,31).  The kidney has been shown to contribute significantly to the 
removal of homocysteine and SAH from the circulation (32) and data suggests it contains 
adequate CBS to compensate for acute or chronic increases in plasma homocysteine (28).  
Taken together, it could be ascertained that the continued observance of 
hypohomocysteinemia in rat models might be due to an irreversible loss of homocysteine via 
the transsulfuration pathway, whereas in human patients homocysteine may also be 
remethylated to methionine by BHMT in the kidney, thereby conserving the homocysteine 
moiety and contributing to the development of hyperhomocysteinemia. 
The observation of global DNA hypermethylation in the livers of ZDF rats is 
particularly intriguing.  DNA methylation is an important modulator of chromatin structure, 
repressor of transposable elements, and regulator of gene expression (33,34).  DNA is 
methylated at cytosine residues within the context of CpG dinucleotides.  The CpG 
sequence is underrepresented as only 1-4% of the genome.  This is proposed to be due to 
selection against the sequence due to its high potential for deleterious effects (35).  
Increasing amounts of 5-methylcytosine increases the chance of point mutations through the 
genome by virtue of the spontaneous deamination (36).  Whereas an unmethylated cytosine 
base is deaminated to uracil, deamination of methylated cytosine produces thymine.  If 
these altered bases go undetected by DNA repair enzymes prior to replication and the 
transition mutation will be maintained and carried on to daughter cells.  Accumulation of 
mutations can contribute to genome instability.  Another possible explanation for adverse 
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effects of genomic hypermethylation might involve hypercondensation of the chromosome.  
Experimental overexpression of DNMT1 was used to induce genomic DNA hypermethylation 
and was associated with chromosomal overcondensation, as well as some cases of 
chromosomal rearrangement and misalignment of sister chromatids (37), which could be 
expected to alter chromosomal segregation during cell division.  Genomic hypermethylation 
was also associated with increased methylation at histone 3 lysine 9 (H3K9) (37).  
Interestingly, increased H3K9 dimethylation has also recently been shown in lymphocytes 
from type 1 diabetic patients and was associated with the promoter regions of many genes 
of inflammatory processes which may contribute to the development of secondary 
complications (38).  Moreover, one of the few reports of genomic DNA hypermethylation in 
clinical studies found that leukocytic DNA hypermethylation  was associated with increased 
inflammation (as measured by plasma interleukin-6 concentrations)  and increased mortality 
in patients with chronic kidney disease (39). 
In this study, digestion of DNA by restriction enzymes followed by radiolabeled 
cytosine incorporation provided an assessment of total DNA methylation at the consensus 
sites for HpaII or BssHII, which represent genomic DNA and CpG island sites respectively.  
Genomic hypermethylation in this study could lead to genic or chromosomal mutations that 
would not be detected by the method used in this study.  Likewise, differential patterns of 
methylation in which the overall level of DNA methylation was unchanged would not have 
been detected.  Subsequent studies will be designed to assess DNA methylation in a more 
site-specific manner. 
The pathophysiology of ZDF rats is characterized by obesity, hyperglycemia, 
hyperinsulinemia, hyperlipidemia, and hypertension (40).  ZDF rats develop 
hyperinsulinemia and insulin resistance before 7 wks of age, with an incremental initial drop 
in elevated insulin levels around 8 wks of age, blood glucose levels rise and the animals 
become overtly diabetic by 12 wk of age (41), which we describe here as the early diabetic 
state.  Although insulin levels continue to drop due to the phenomena of pancreatic β-cell 
exhaustion, ZDF rats may remain hyperinsulinemic relative to lean controls well into the 
advanced diabetic stage (21), as was also observed in this study.   In contrast, as a type 1 
models of diabetes, STZ- or alloxan-induced diabetes results in hyperglycemia, but a lack of 
insulin production due to selective destruction of the pancreatic beta cells.  Treatment of rats 
or hepatic cell lines with glucocorticoids, such as dexamethasone or triamcinolone, has also 
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been shown to induce expression of MAT, GNMT, BHMT, and CBS at the transcriptional 
level (4,11,12,42,43).  Insulin administration has been shown to prevent these alterations in 
both rats and/or cell lines.  Interestingly, in healthy individuals insulin stimulates 
transmethylation, as well as transsulfuration flux (44).  Insulin treatment of untreated HepG2 
hepatocarcinoma cells was also capable of inducing MAT activity (45).  Thus insulin could 
be seen as playing a role in elevation of SAM concentrations and the metabolic 
perturbations in the early diabetic state.  Separate treatment of HepG2 cells with glucose 
also resulted in stimulation of MAT activity and furthermore, induced genomic 
hypermethylation (45).  Several recent cell culture studies that were designed to mimic 
hyperglycemia have shown alteration of histone modification which persist after glucose 
levels are restored to normal.  Based on genome-wide profiling of specific histone 
modifications, these studies implicate hyperglycemia in the epigenetic regulation of 
pathways involved in signal transduction, oxidative stress, immune function, and 
inflammation (38,46-49).  The bulk of evidence indicates that aberrations of methyl group 
metabolism and epigenetic regulation are likely due to the combination of hyperglycemia, a 
lack of insulin/insulin resistance and/or elevated counter-regulatory hormones. Alternatively, 
to explain where the response differs with respect to diabetes classification, we might look to 
c peptide for new insight. In both human patients and animal models, C peptide is increased 
in type 2 diabetes, but markedly decreased in type 1 diabetes (50-53). C peptide has been 
shown to be involved in cell signaling – with many insulinomimetic properties - and 
furthermore, has been implicated in the development of vascular inflammation and 
atherosclerosis in type 2 diabetes (50).  However, the actions of c peptide in type 2 diabetics 
are largely uncharacterized and may provide an opportunity for investigation into the 
differences in the pathology of type 1 and type 2 diabetes.     
In summary, we have shown that methyl group and homocysteine metabolism was 
altered in a tissue-specific manner during the progression of type 2 diabetes in the ZDF rat.  
The response to the diabetic condition and elevated SAM concentrations appears to be 
more tightly regulated in the liver than the kidney.  Although there are many commonalities 
in the regulation of methyl group and homocysteine metabolism in type 1 and type 2 
diabetes, the impact on epigenetic regulation varies between the two conditions.  
Abnormalities of enzymatic regulation and key metabolite concentrations have been 
observed as early as 5 weeks of age (9) and we have shown hepatic DNA hypermethylation 
at 12 weeks of age in ZDF rats.  Data are lacking prior to these timepoints, thus it is unclear 
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when the abnormalities of methyl group metabolism and epigenetic regulation are initiated in 
the ZDF rat.  However, it is clear that perturbations of methyl group metabolism and aberrant 
DNA methylation are an early event in the development of a diabetic condition in the ZDF rat 
with potentially long-lasting effects due to the generally stable nature of epigenetic 
mechanisms of regulation. 
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CHAPTER SIX: Summary and conclusions 
 
General discussion of study results 
Our working hypothesis was that sustained induction of glycine N-methyltransferase 
(GNMT), by either retinoids or a diabetic condition, would lead to a functional methyl 
deficiency, whereby methyl groups would be unavailable for other methyltransferase 
reactions, such as DNA methylation.  We expected that changes in epigenetic regulation, 
i.e. DNA methylation, would be associated with adverse effects, such as hepatotoxicity.  
Aberrant epigenetic regulation also represents a possible mechanistic link to 
hepatocarcinogeneis and the development of the secondary complications of diabetes, 
which will be addressed in future studies.  The three studies presented here studied retinoic 
acid and diabetes as inducers of GNMT activity and abundance.  The induction of GNMT by 
retinoic acid or diabetes was observed at all measured timepoints, although there were not 
consistent changes in DNA methylation status, suggesting an influence of other regulatory 
factors.  Methyl group and homocysteine metabolism, as well as epigenetic mechanisms, 
are intricately tied to health and disease.  This information may help in optimization of health 
or prevention/treatment of disease by laying the foundation for future studies which will 
assess gene-specific changes in epigenetic regulation and determine the impact of 
additional regulatory factors. 
Here we have demonstrated that induction of hepatic GNMT by all-trans-retinoic acid 
(RA) treatment (3x weekly) was sustained for at least 6 months, but was not associated with 
changes in DNA methylation status.  Although DNA methylation status was unaltered, the 
possibility remains that other important transmethylation reactions were compromised. 
However, given the rapid clearance of RA from the plasma and lack of storage in the liver, it 
is possible that daily RA treatment is necessary for alteration of DNA methylation status and 
also suggests the possible influence of other regulatory mechanisms in addition to the 
upregulation of GNMT, which was sustained despite non-daily administration of RA.  
Furthermore, RA treatment had adverse effects on hematopoiesis and plasma glutathione 
levels.  This research contributes to the growing body of knowledge that will be useful in the 
risk-benefit analysis of RA therapies. 
 106 
 
  In contrast to the response to RA, global DNA methylation status was modulated by 
type 1 and type 2 diabetes, though the effect was not the same in both diabetic conditions.  
Despite largely similar patterns of tissue-specific and time-dependent alterations of methyl 
group and homocysteine metabolism, genomic DNA was hypomethylated in the 
streptozotocin (STZ)-induced type 1 diabetic rat liver, but genomic DNA hypermethylation 
was observed in the livers of Zucker (type 2) diabetic fatty (ZDF) rats.  These reports of 
tissue-specific methyl group and homocysteine metabolism, and particularly the association 
with aberrant DNA methylation status, during the progression of diabetes are novel findings. 
 
Methyl group and homocysteine metabolism in diabetes 
The aberrations of methyl group and homocysteine metabolism in diabetic rats are 
time- and tissue-specific.  Hepatic alterations are an early event in both type 1 and type 2 
diabetes.  In the early diabetic and advanced diabetic condition in the STZ-diabetic rat, we 
have reported increased hepatic GNMT, phosphatidylethanolamine N-methyltransferase 
(PEMT), betaine-homocysteine S-methyltransferase (BHMT), and cystathionine β-synthase 
(CBS) activity and/or abundance, whereas methionine synthase (MS) activity was 
decreased.  The Brosnan group has reported upregulation of enzymes of all four pathways 
of hepatic homocysteine metabolism in the prediabetic ZDF rat (1).  When data from the 
studies presented here are taken together with the data of the Brosnan group, it appears 
that many alterations of methyl group and homocysteine metabolism are present in the early 
diabetic condition, whereas only a few characteristics are more persistent and are also 
observed in the advanced diabetic condition, such as the upregulation of hepatic GNMT and 
BHMT, as well as hypohomocysteinemia.   
Hypohomocysteinemia may result in rat models of diabetes due to the lower 
expression levels of BHMT in the rat liver in comparison to the human liver (2).  It has also 
been shown that methionine synthase and urinary disposal are not major routes for the 
removal of homocysteine in neither the healthy nor STZ-diabetic rat liver (3,4).  However, 
the kidney has been shown to remove 40% of SAH (5) and at least  ~20% of homocysteine 
from the circulation (6), thereby it must be assumed that in the rat kidney homocysteine is 
irreversibly catabolized by the transsulfuration pathway, which has been shown 
experimentally as well (7).  In the human kidney, homocysteine may also be remethylated to 
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methionine by BHMT, thereby conserving the homocysteine backbone and possibly 
contributing to the development of hyperhomocysteinemia, particularly in the case of 
diabetic nephropathy in which transsulfuration flux has been shown to be decreased (8).  
Although hyperhomocysteinemia has not been observed even in the advanced diabetic 
conditions in the diabetic rat models used in these studies, downregulation of CBS has been 
implicated in the development of renal dysfunction in the Dahl salt-sensitive hypertensive rat 
(9) and both STZ-diabetic and ZDF rats at least had trends towards decreased CBS 
abundance in the kidney.  It is of interest to note that renal homocysteine levels were 
significantly decreased at 12 wk in the ZDF rats, whereas there was no significant difference 
in advanced diabetes.  Given that signs of renal dysfunction are evidence as early as 14 
weeks of age in the ZDF rat (Anderson and Rowling, unpublished observations), this might 
suggest altered renal handling of homocysteine with the progression of renal disease in this 
model.  
By looking more closely at the data from the ZDF study, we are given greater insight 
into the roles of the liver and kidney in the early and advanced diabetic conditions (Figure 
1).  The enzymes of the liver appear to be tightly regulated as evidenced by increased 
GNMT and CBS activity and/or abundance associated with increased intracellular SAM 
concentration in the early diabetic condition.  When hepatic SAM concentrations are similar 
to controls in the advanced diabetic condition, several methyltransferases are still 
upregulated at the level of mRNA abundance or protein activity and abundance, but CBS 
abundance is not different from controls and BHMT mRNA abundance was increased, likely 
indicating a conservation of methionine.  In contrast, the enzymes of methyl group and 
homocysteine metabolism in the kidney are affected to a lesser extent and metabolite 
concentrations seem to generally reflect changes in liver and circulation.  The only alteration 
at the transcriptional/translational level noted in the kidney was a trend towards decreased 
CBS protein abundance in early diabetes. The increase in GNMT activity at 21 weeks was 
not accompanied by increased GNMT protein abundance, suggesting regulation only at the 
post-translational level.  In the STZ-diabetic rat kidney there was only a transient induction in 
renal GNMT and CBS protein abundance was decreased.  In both the type 1 and type 2 
diabetic rat liver, the tissue-specific perturbations of methyl group and homocysteine 
metabolism preceded or were concurrent with tissue-specific changes in DNA methylation 
status, with abnormal levels of DNA methylation found in the liver, but not the kidney. 
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Figure 1.  Effects of early (12 wk) and advanced (21 wk) diabetes in the ZDF rat on key 
regulatory proteins and metabolites of methyl group and homocysteine metabolism  
 
Epigenetic regulation in the diabetic state 
For the analysis of epigenetic regulation presented within this work, DNA methylation 
status was assessed by digestion of DNA with methylation-specific restriction enzymes, 
followed by cytosine extension.  Expression of epigenetic regulatory proteins was estimated 
by using real-time reverse-transcriptase PCR for determination of relative mRNA abundance 
of the DNMTs and MBDs.  The DNA methylation assay was first published by Pogribny et al 
(10) and the first published use of the assay by our lab is presented in Chapter 4.  This 
assay was chosen because it was been shown to be sensitive, gives a linear response, and 
is not affected by DNA damage (though it may be noted that damage was not noted in our 
isolated DNA when run out on an agarose gel).  In the initial workup of the assay the linear 
response was verified and we have taken care to include appropriate controls as well.  
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Digestion of DNA by MspI is not methylation-specific and cleaves at all methylated sites, 
whereas 3T3 fully-methylated DNA was used as a negative control.  Use of these controls 
verified that the percent methylation for control samples fell within the expected range of 70-
90% (11).  Use of this method was appropriate for an initial study of DNA methylation status, 
though it is limited in that it only assesses overall methylation status.  We cannot rule out 
that there may be gene-specific changes in methylation status that are undetected by this 
assay or that there are changes in methylation patterns, without changing the overall level of 
CpG island methylation.  We anticipate that gene-specific assessment will be the goal of 
future studies. 
Some of the most intriguing findings of these studies were the detection of hypo- and 
hypermethylation of genomic DNA in the type 1 and type 2 diabetic rat liver respectively.  
Our lab group has found hepatic genomic DNA hypomethylation in type 1 diabetes is 
observed not just in the STZ-diabetic rat, but also in the genetic nonobese diabetic mouse 
model (12).  Alterations of genomic DNA methylation status have been associated with 
increased genomic instability.  Genomic DNA hypomethylation is associated with genomic 
instability due to a more relaxed chromatin structure and fewer repressive mechanisms 
which facilitates a greater number of recombinational events, movement of transposable 
elements, loss of imprinting, and overexpression of genes, specifically oncogenes (13).  
Thus, genomic hypomethylation is a hallmark of cancerous tissue, including hepatocellular 
carcinomas in rat models and in human patients (13-16).  Epidemiological studies support a 
link between diabetes and cancer as evidenced by an increased incidence of liver cancers 
of both type 1 and/or type 2 diabetic patients (17-20). 
On the opposite end of the spectrum, genomic hypermethylation could increase 
genomic instability by altering chromatin and overall chromosomal structure, as well as by 
the accumulation of point mutations.  Increasing amounts of methylated cytosine increases 
the chance of point mutations throughout the genome due to spontaneous deamination (21).  
Unmethylated cytosine bases are deaminated to uracil, whereas deamination of methylated 
cytosine produces thymine, a transition mutation.  If this TpG-CpG mismatch goes 
undetected by DNA repair enzymes prior to replication, the transition mutation will be 
maintained in future cells.  Another possible explanation for adverse effects of genomic 
hypermethylation come from experimental overexpression of DNMT1 which induced 
genomic DNA hypermethylation and was associated with chromosomal overcondensation, 
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as well as some cases of chromosomal rearrangement and misalignment of sister 
chromatids (22), which could be expected to alter chromosomal segregation during cell 
division.  Genomic hypermethylation was also associated with increased methylation at 
histone 3 lysine 9 (H3K9) (22).  Interestingly, increased H3K9 dimethylation has also 
recently been shown in lymphocytes from type 1 diabetic patients and was associated with 
the promoter regions of many genes of inflammatory processes which may contribute to the 
development of secondary complications (23).  Moreover, one of the few reports of genomic 
DNA hypermethylation in clinical studies found that leukocytic global DNA hypermethylation  
was associated with increased inflammation (as measured by plasma interleukin-6 
concentrations)  and increased mortality in patients with chronic kidney disease (24).  Thus, 
both hyper- and hypomethylation of genomic DNA have been associated with adverse 
clinical outcomes which may be relevant to the diabetic condition.   
 
Possible factors regulating metabolic and epigenetic aberrations in diabetes 
Given the relationship between homocysteine metabolism and epigenetic patterns 
with the pathogenesis of disease, it is critical to determine which factors might play a role in 
regulating these processes.  In the RA-treated rat, it is likely that RA complexed with its 
receptors acts directly on the GNMT promoter to increase transcription.  However, in the 
diabetic condition, there are numerous potential hormonal influences including 
glucocorticoid, insulin, incretin hormones and other insulin-related hormones such as c 
peptide and insulin-like growth factor 1 (IGF-1) which may play a role.  Although diabetes 
perturbations of methyl group and homocysteine metabolism were concurrent with or 
preceded aberrant DNA methylation levels, when taken together the data from the chronic 
RA treatment study, it appears that there are also other influencing factors in each of these 
conditions that contribute to dysregulation of DNA methylation. 
A diabetic condition could be described, in part, as hyperglycemia due to a lack of 
insulin or lack of response to insulin, resulting in a relatively greater effect of glucocorticoids.  
Similar to the effects of a diabetic condition, treatment of rats or hepatic cell lines with 
glucocorticoids, such as dexamethasone or triamcinolone, has been shown to increase 
MAT, GNMT, BHMT, and CBS mRNA abundance, protein abundance, and/or activity levels 
(25-29).  Insulin administration attenuated these effects in both rats and/or cell lines which 
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were diabetic or treated with glucocorticoids.  However, insulin treatment of HepG2, human 
hepatocarcinoma cells, cultured in otherwise standard media was also capable of inducing 
MAT activity (30).  Furthermore, in healthy individuals insulin stimulates transmethylation, as 
well as transsulfuration flux (31).  In the short term, this might be expected to protect against 
the accumulation of homocysteine as proposed by the authors, but if hyperinsulinemia 
persists, these changes might be described as an early event in prediabetes or a diabetic 
condition, similar to that observed by the Brosnan group and in our studies of the ZDF rat.  
However, based on treatment of HepG2 cells, hyperinsulinemia alone was insufficient to 
induce alterations of DNA methylation status (30).  However, glucose treatment increased 
MAT activity and induced genomic DNA hypermethylation.  This suggests a critical role for 
insulin and/or hyperglycemia in the dysregulation of hepatic methyl group and homocysteine 
metabolism and it is possible that the period of hyperinsulinemia in the prediabetic state of 
type 2 diabetes may have a unique influence on metabolic and epigenetic perturbations, 
though no immediate direct effects on DNA methylation status have yet been observed.  
This might be further investigated in cell culture by combining hyperinsulinemic and 
hyperglycemic treatments and determining the impact of concurrent treatment vs. initial 
treatment with insulin followed by co-treatment to look for additive or synergistic effects.  
Alternatively, treating healthy rats with insulin could be used to determine the in vivo effects 
on methyl group metabolism and epigenetic regulation. 
There are a wide variety of additional factors that are influential in the diabetic 
conditions including hormonal factors such as glucagon-like peptide-1 (GLP-1), glucose-
dependent insulinotropic polypeptide (GIP), insulin-like growth factor-1 (IGF-1) and c 
peptide.  Additionally, many of these parameters are affected by common pharmaceutical 
and lifestyle interventions for the treatment of diabetes.  GLP-1 and GIP are also known as 
the incretin hormones and both hormones act directly on the pancreas to increase 
pancreatic beta cell proliferation, insulin synthesis and secretion via direct effects (32).  
GLP-1 also enhances glucose uptake and storage through effects on the central nervous 
system.  Likewise, IGF-1 has insulin-sensitizing effects, acts directly on the pancreatic beta 
cells, and additionally, has insulinomimetic effects (33,34).   Treatment with IGF-1, agents 
which decrease the incretin hormones, or agonists of incretin receptors are the focus of 
many anti-diabetic therapies, which are often successful in slowing the progressing of type 2 
diabetes and minimizing complications (32-35).  However, these medications do not work 
indefinitely and do not abrogate all metabolic perturbations of type 2 diabetes (35).  Studies 
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of insulin-sensitizing interventions in the ZDF rat show a similar pattern.  An exercise 
intervention consisting of 8 wk of treadmill running was successful in improving insulin 
sensitivity and preventing increases in blood glucose in the ZDF rat at 14 wk of age (36).  
However, fasting serum insulin levels continued to rise slowly in ZDF rats despite the 
exercise intervention, which might suggest the course of the disease was only delayed.  The 
effect of exercise on methyl group and homocysteine metabolism was not determined in this 
study.  However, in the insulin resistant (not diabetic) Zucker fatty rat, three weeks of 
troglitazone treatment increased hepatic CBS activity which was proposed to have 
contributed to the observed decrease in plasma homocysteine, but the hepatic SAM:SAH 
ratio was decreased relative to untreated Zucker fatty rats (37).  This data from the strain 
from which the ZDF rat was selectively bred suggests that insulin-sensitizing drugs may 
modulate methyl group and homocysteine metabolism in the prediabetic condition, though 
this limited evidence does not fully explain what effect these alterations may have on 
transmethylation reactions.  Troglitazone works as an activator of PPARα and γ, suggesting 
the possible involvement of yet another regulatory pathway.  Whereas the factors discussed 
thus far affect beta cell function and insulin action specifically, another possibility lies in c 
peptide which, like insulin, is differentially regulated in type 1 and 2 diabetic conditions and 
also has independent cellular signaling mechanisms (38).  
 
Future research  
There are several areas towards which future research efforts could be directed.  
Here are four potential aims: i) perform a more in-depth study of perturbed epigenetic 
regulation in type 1 and type 2 diabetes, ii) investigate possible factors involved in the 
different epigenetic response in advanced type 1 and type 2 diabetic conditions, iii) define 
the mechanisms by which modulators of methyl group and homocysteine exert their effects, 
and iv) develop dietary therapies for optimal health, prevention of disease, or treatment of 
adverse effects. 
 The results from the studies presented herein indicate the presence of diabetes-
induced alterations of DNA methylation status.  Thus far we have shown this as overall net 
changes in DNA methylation, but to gain a greater understanding of the biological 
significance of said aberrations will require localization of the sites at which methylation 
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status is changed.  This information will be crucial for linking alterations of methyl group 
metabolism and epigenetic regulation to the development of secondary complications of 
diabetes, which was not addressed by the current studies.  To accomplish this, experiments 
should be designed to assess both specific changes in epigenetic regulation as well as the 
progression of secondary complications of diabetes.   
For the determination of specific alterations of epigenetic regulation by DNA 
methylation the most comprehensive approach would use of genome-wide analyses such as 
the Methyl-Seq technique, which utilizes next-generation sequencing tools, or DNA 
methylation-specific microarray.  Each technique offers advantages: Methyl-Seq offers a 
nonbiased analysis and will analyze changes in DNA methylation at both genic and 
nongenic sites (39), whereas microarrays are also available for the entire genome (40) or 
specifically covering all known promoter sites for genes and miRNAs, as well as all CpG 
islands (41), which may help to focus in on the most biologically-relevant changes.  For the 
study of individual genes, bisulfite treatment and methylation-specific PCR techniques could 
be used.  Based on recent genome-wide analyses of histone modifications in cultured and 
primary cells from diabetics which revealed widespread and gene-specific alterations of 
histones (23,42-45), as well as our data which demonstrated changes in overall DNA 
methylation levels, we anticipate that we will likewise find changes in DNA status at specific 
sites within the genome.  Alterations of DNA methylation status are expected in pathways 
involved in signal transduction, oxidative stress, immune function, and inflammation.  
Notably, we detected a transient change in methylation status in the CpG islands in the 
STZ-diabetic rat; it is possible that a similar transition occurred in the ZDF rat, but was not 
captured by our study based on the timepoints at which we collected our samples.   
The development of secondary complications and their relationship to epigenetic 
alterations observed in diabetic conditions will require more thorough assessments of kidney 
and vascular function.  Our studies used basic assessments of renal dysfunction by 
comparing relative renal weights and plasma creatinine concentrations.  Although these 
methods are have been used by others in diabetic rats (46,47), renal dysfunction might be 
more adequately assessed in future studies by histological examination and measurement 
of additional circulatory and urinary substances such as has been performed previously in 
diabetic rat models (47).  Plasma and urinary levels of hemoglobin, albumin, and creatinine, 
as well as plasma cystatin c would all be appropriate biochemical measures (46-48).   
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Plasma cystatin c is a more recently established biomarker of renal dysfunction that has the 
additional advantage of not being affected by muscle mass or malignancy and would be 
expected to be appropriate for use in a diabetic population (49,50).  Histochemistry and 
immunohistochemistry methods utilizing hematoxylin and eosin y staining, alone or in 
combination with antibodies against transforming growth factor-β, could be utilized for the 
assessment of alterations of glomerular structure and detection of renal fibrosis.  For future 
studies of cardiovascular disease, we have proposed to assess the progression of 
atherosclerosis as indicated by the vascular response to vasodilators (51), time to 
thrombosis following injury (52), and platelet coactivation activity (53).  In similar studies of 
ZDF rats, early indicators of vascular and renal dysfunction are noted around 14-16 weeks 
of age (54, Anderson and Rowling, unpublished observations) and at necropsy we noted 
gross morphological abnormalities in the kidneys of ZDF rats in the advanced diabetic state. 
The second and third aims relate to increasing understanding of the specific factors 
that are known to alter methyl group metabolism and epigenetic regulation.  The divergent 
regulation of DNA methylation status by type 1 and type 2 diabetic conditions is an intriguing 
finding and efforts should be made to determine possible mediators of this effect.   As has 
been previously discussed, one possibility lies in the timing of insulin exposure based on 
evidence that insulin attenuates abnormal methyl group and homocysteine metabolism in 
type 1 diabetic models and patients (8,27,28,55, Nieman and Schalinske, unpublished 
observations), whereas hyperinsulinemia in healthy individuals and otherwise untreated cell 
culture models was associated with increased transmethylation and transsulfuration (30,31).  
At the surface, it appears that the effect of c peptide might also be a promising target of 
investigation because it is differentially expressed in type 1 and type 2 diabetes, has some 
insulin-like effects, but is also biologically active by a separate receptor, and its functions are 
likely not yet fully characterized (38).  We, and others, have shown that many other 
hormones or biologically active compounds have a profound impact on methyl group and 
homocysteine metabolism (56).  Studies addressing the mechanisms by which these 
compounds - largely ligands for nuclear receptors such as thyroid hormones, retinoids, 
glucocorticoids – exert their regulatory effects may help provide for the development of a 
more unified theory of regulation of methyl group and homocysteine metabolism.   
 Lastly, it would be desirable to be able to formulate some form of dietary therapy to 
ameliorate the effects of perturbed methyl group metabolism.  Methyl group 
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supplementation might be used in type 1 diabetes with the goal of providing adequate levels 
of methyl groups for all SAM-dependent transmethylation reactions.  When considering 
supplementation of methyl groups there are many combinations of donors and cofactors that 
could be provided; however, the most efficient approach would be to use an inclusive 
mixture that has been shown to be optimally effective in previous studies (57).  Thus, 
supplementation groups might receive a modification of our standard semi-purified AIN93 
diet containing (per kg diet): methionine, 3g; choline, 5 g; betaine, 5 g; folate, 5 mg; B12, 0.5 
mg; and B6, 10 mg (57,58).  A number of studies have also shown that SAM can be 
provided via the diet and is bioavailable in both rats and humans (59-61).  It is also of 
interest to note that SAM has recently been reported to increase insulin sensitivity (62) and 
this compound is available over-the-counter.  This makes it an attractive option based on 
consumer availability and also lends particular importance to gaining a greater 
understanding of the effects of taking such a supplement since many individuals may 
already be using this product.  
Another possibility for dietary intervention might be through altering methionine and 
cysteine content.  We have previously shown that methionine supplementation or feeding of 
egg white protein (a protein with a higher methionine:cysteine ratio than the casein 
standard) can alter methyl group and homocysteine metabolism (63,64).   Feeding excess 
methionine (10% casein plus 0.3% vs. 0.5-2.0% methionine) results in a dose-dependent 
increase in hepatic GNMT (63) and it has long been known that excess methionine and 
SAM stimulates transsulfuration (65).  When egg white protein was substituted for casein, 
hepatic GNMT and BHMT activities were increased and plasma homocysteine was 
decreased (64).  Given this upregulation of specific transmethylation reactions and 
transsulfuration in response to increased methionine or methionine:cysteine ratio, it stands 
to reason that feeding diets with a protein with a low methionine:cysteine ratio or by 
supplementing cysteine, the drive towards increased transmethylation and transsulfuration 
might be reduced.  A recent study shows promise for this approach given that 8 wks of L-
cysteine supplementation lowered blood glucose levels and inflammatory markers in ZDF 
rats relative to saline-treated controls (66).  Plasma glutathione levels were unchanged 
between groups, but we have not shown this to be altered in the ZDF rat and data was not 
collected on any other key regulatory proteins of metabolites of methyl group or 
homocysteine metabolism.  This hypothesis certainly warrants future investigation. 
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In addition to the differences in methyl group utilization, specifically with regards to 
DNA methylation, between the type 1 and type 2 conditions, challenges to implementation of 
dietary therapies include timing effects and confounding factors such as dietary intake and 
enzyme polymorphisms.  The timing of dietary intervention has been shown to be 
particularly important, especially with regards to influencing epigenetic mechanisms.  DNA 
methylation and other forms of epigenetic regulation seem to be particularly vulnerable to 
change during the perinatal and pubertal periods and in aging (67,68).  Likewise, it appears 
that in the progression of disease, it is likely that there is only a specific window of time in 
which the effects may be prevented or reversed, as has been shown in the methyl-deficient 
diet model of hepatocarcinogenesis (69).  Furthermore, in human populations, the response 
of homocysteine and folate one-carbon metabolism to dietary interventions has been shown 
to be affected by polymorphisms within these pathways (70-72) 
 
Overall conclusions 
 In summary, these studies have demonstrated the changes of methyl group and 
homocysteine metabolism in long-term intermittent retinoid treatment, as well as during the 
progression of type 1 and type 2 diabetic conditions.  Furthermore, we have characterized 
perturbations of overall epigenetic regulation by DNA methylation in a diabetic condition.  In 
the diabetic conditions, alterations in methyl group and homocysteine metabolism preceded 
or were concurrent with changes in epigenetic regulation.  Although GNMT was upregulated 
by retinoid treatment and in both diabetic conditions, the effects on DNA methylation status 
varied.  This disparity suggests a role for additional factors impacting epigenetic regulation.  
Future studies should be conducted with the goal of elucidating which factors are most 
important in the modulation of methyl group and homocysteine metabolism, as well as 
regulation of DNA methylation patterns.  It will also be of the utmost interest to determine the 
specific nature of the epigenetic alterations observed here and greater efforts must be made 
to identify potential linkages between these changes and the development of diabetic 
complications, thus providing insight into the biological significance of abnormal methylation 
in diabetes and potentially providing targets for future therapies. 
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APPENDIX A. Chapter 4 Supplemental Data 
 
Plasma creatinine was significantly decreased in the STZ-diabetic rat at 8 wk. 
  
Plasma creatinine (mg/dL) 
  
Time (weeks) Control STZ-Diabetic p-value 
2 1.71 ± 0.19 1.60 ± 0.22 0.712 
4 2.08 ± 0.23 1.45 ± 0.19 0.065 
8 2.28 ± 0.30 0.88 ± 0.15* 0.015 
Data are means ± SEM (n = 5). *indicates significantly different from control, p < 0.05. 
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APPENDIX B.  Chapter 5 Supplemental Data 
 
Age (weeks)
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ZDF
 
Body weights of lean and ZDF rats in the study of advanced diabetes.  Data are means, 
statistical analysis at 21 wk presented in Table 2 within the text.  
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Hepatic mRNA abundance of key proteins of epigenetic regulation was unchanged at 12 wk 
in ZDF rats compared to lean controls 
    Mean fold induction     
Target   Lean ZDF   p-value 
DNMT1 
 
1.00 ± 0.23 0.97 ± 0.33 
 
0.944 
DNMT3a 
 
1.00 ± 0.66 0.20 ± 0.10 
 
0.215 
DNMT3b 
 
1.00 ± 0.44 0.33 ± 0.13 
 
0.150 
MBD1 
 
1.00 ± 0.51 0.60 ± 0.32 
 
0.504 
MBD2 
 
1.00 ± 0.73 0.18 ± 0.06 
 
0.247 
MBD3 
 
1.00 ± 0.68 0.17 ± 0.11 
 
0.213 
MBD4 
 
1.00 ± 0.70 0.11 ± 0.09 
 
0.247 
MeCP2   1.00 ± 0.65 0.15 ± 0.08   0.429 
Data are means ± SEM, * indicates significant difference, P < 0.05 
 
 
 
 
